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Abstract 
Neurological disorders – disorders of the brain, spine and associated nerves – 
are a leading contributor to global disease burden with a sizable economic cost. 
Adeno-associated viral (AAV) vectors have emerged as an effective platform for 
CNS gene therapy and have shown early promise in clinical trials. These trials 
involve direct infusion into brain parenchyma, an approach that may be sub-
optimal for treatment of neurodegenerative disorders, which often involve more 
than a single structure in the CNS. However, overall neuronal transduction 
efficiency of vectors derived from naturally occurring AAV capsids after systemic 
administration is relatively low. We have developed novel capsids AAV-AS and 
AAV-B1 that lead to widespread gene delivery throughout the brain and spinal 
cord, particularly to neuronal populations. Both transduce the adult mouse brain 
>10-fold more efficiently than the clinical gold standard AAV9 upon intravascular 
infusion, with gene transfer to multiple neuronal sub-populations. These vectors 
are also capable of neuronal transduction in a normal cat. We have 
demonstrated the efficacy of AAV-AS in the context of Huntington's disease by 
knocking down huntingtin mRNA 33-50% after a single intravenous injection, 
which is better than what can be achieved by AAV9 at the particular dose. AAV-
B1 additionally transduces muscle, beta cells, pulmonary alveoli and retinal 
vasculature at high efficiency, and has reduced sensitivity to neutralizing 
antibodies in human sera. Generation of this vector toolbox represents a major 
step towards gaining genetic access to the entire CNS, and provides a platform 
to develop new gene therapies for neurodegenerative disorders. 
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CHAPTER I 
Introduction  
  
2 
Viral vectors for gene therapy of neurological disorders 
 
In recent years, gene therapy using viral vectors – encoding a therapeutic gene 
or inhibitory RNA into a “gutted” viral capsid and supplying it to the nervous 
system - has emerged as a clinically viable option for therapy of brain disorders 
largely due to the success and safety of the current generation of virus-based 
vectors1. In general viral vectors have proven more efficient at gene delivery in 
vivo than synthetic nanoparticle and liposome vectors, and in most diseases the 
goal is to transduce as many affected cells as possible. Within the nervous 
system, phase 1/2 clinical trials have shown benefit for several neurologic 
diseases involving replacement of defective genes. This includes: restoration of 
vision, at least for an extended period, in Leber’s congenital amaurosis (LCA) 
using adeno-associated virus (AAV) vectors2; curtailment of further brain 
neurodegeneration in the brain in metachromatic leukodystrophy (MLD)3 and 
adrenoleukodystrophy (ALD)4 using ex vivo genetic modification of hematopoietic 
stem cells with lentivirus vectors; and safety for oncolytic vectors in clinical trials5. 
Success has also been reported in blocking human immunodeficiency virus (HIV) 
infection in a single individual using ex vivo gene editing of autologous CD4 T 
cells to disrupt the viral receptor gene CCR56. 
 
It is hardly surprising that viruses have led the field in gene therapy, as they have 
evolved to deliver their genes efficiently in the form of RNA or DNA into 
mammalian cells. In many cases their aim is to replicate in and kill the host cell in 
the process, as in the case of adenovirus and herpes simplex virus (HSV). In 
other cases they may be non-pathogenic such as AAV, or may either become 
latent in the host cell for long periods (e.g. HSV in trigeminal neurons) or 
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integrate into the host cell genome at different sites as with retrovirus and 
lentivirus. Viruses have evolved very efficient mechanisms to deliver their 
genome into cells. In the case of HSV and retrovirus/lentivirus their genome is 
carried within a proteinaceous capsid surrounded by a lipid membrane envelope. 
This envelope can efficiently fuse with the plasma membrane of the cell 
delivering its contents directly into the cytoplasm with subsequent release of 
nucleic acids from the capsid, and either conversion to DNA (in the case of 
retro/lentivirus vectors) or delivery of DNA (in the case of HSV) into the cell 
nucleus. Other viruses, such as AAV and adenovirus, have a proteinaceous 
capsid that is taken up by endocytosis and have evolved ingenious means to 
escape the endosome/lysosome compartment to deliver the viral DNA to the 
nucleus. By “gutting” the virus of its own genes and just retaining the packaging 
signals, one can package viral vectors in culture using viral genes in trans for 
replication and virus structure and generate an efficient delivery vehicle for the 
transgene of interest with no viral genes. 
As in pharmacology, it is a therapeutic advantage if the cause of the disease 
(target) is known, as in monogenic hereditary diseases. For these diseases, gene 
therapy strategies using virus vectors include gene replacement by bringing in a 
normal copy of a defective gene using AAV vectors that establish themselves as 
stable “episomes” in the cell nucleus, and lentivirus vectors that integrate 
transgenes into the genome. Both AAV and lentivirus vectors are capable of 
infecting dividing and non-dividing cells, but the latter are a better choice for 
permanent modification of dividing cell populations as genomic integration 
ensures the progeny generated from the primary target cell is also genetically 
modified. These same vectors can be used to deliver siRNAs (shRNAs)/miRNAs 
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that can downregulate a dominant-negative mutant mRNA/protein, sometimes 
also decreasing copies of the normal mRNA.  In the future with CRISPR or other 
gene editing technology combined with virus vectors, it should be possible to 
correct gene defects in recessively inherited diseases and to eliminate mutant 
genes in dominantly inherited diseases in mammalian brain7.  For diseases of 
unknown etiology, strategies have evolved to deliver neurotrophic factors, 
neurotransmitters, compensatory proteins, and selectively toxic proteins into the 
brain. 
Some general principles of intervention are becoming clear. 1) Treat early. 
Excluding prenatal gene therapy, which is not considered ethical at this stage, 
and given that most neurologic diseases have progressive sequelae, it is best to 
begin treatment as early as possible. For example, for spinal muscular atrophy 
(SMA) in which motor neurons are lost leading to death within months for some 
babies, AAV gene replacement is being tested in babies 2-9 months of age 
(NCT02122952). In MLD and ALD where gene therapy can arrest 
neurodegeneration, it is important to treat before extensive damage to the brain 
has already occurred3, 4.  2) Too much has to be okay. With the current 
generation of promoters, the levels of transgene expression cannot be regulated. 
You have the choice of using strong or weak, constitutive or cell specific 
promoters, but not of adjusting levels of expression or turning off expression after 
delivery. 3) Transgene size is limited.  The two vectors for which we have the 
most clinical experience, AAV and lentivirus, have a limited transgene cassette 
capacity (includes regulatory sequences, promoter, cDNA, and polyA sequence, 
etc.), with a maximum size of about 4-5 kb for AAV and about 8.5 kb for lentivirus. 
For some hereditary diseases, such as ataxia telangiectasia or neurofibromatosis 
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type 1 (NF1) with cDNAs of 9.6 kb and 8.4 kb respectively, this presents a 
difficult hurdle. In the case of dystrophin (11 kb), mutated in Duchenne’s 
muscular dystrophy, a condensed version of the gene (minigene) has been 
developed which lacks repeat sequences and fits into an AAV8. 4) Pick realistic 
outcome measures. It is difficult to monitor benefit if the natural history of the 
disease is variable and the phenotypic traits are not quantitative and are 
protracted over time. For example, neurotrophic therapy in Parkinson’s disease 
(PD) may work, but the outcome measures are subjective and the time to 
measureable clinical improvement may be unrealistically long9.  Realistic 
outcome measures include, for example, metabolite levels, lesion size using a 
variety of imaging methods, and nerve conduction velocity, with improvements 
occurring in the scale of months. 5) You only get one shot. For now, given the 
immunogenicity of viral vectors, efficient delivery will only occur on the first 
exposure to the vector. Thus, it is a disservice to the patients to try non-
therapeutic doses that may exclude the patient from future doses deemed 
therapeutic. This is a difficult problem as the increasing dose regime is an 
inherent part of the evaluation of toxicity in a phase 1 trial. 
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Which vector – why and when? 
 
A number of different viruses have been explored for gene delivery or cancer 
oncolytic therapy. The viruses most commonly used in clinical trials include 
retrovirus vectors, lentivirus vectors, adenovirus vectors, herpes simplex virus 
type 1 (HSV-1) and AAV vectors. 
 
Retroviral vectors derived from Moloney murine leukemia virus (MoMLV) were 
the first vectors to be used for FDA-approved clinical trials. While direct in vivo 
administration does not result in a therapeutic outcome10, pseudotyped retroviral 
vectors has been used clinically for ex vivo correction in human progenitor cells, 
followed by autologous transplantation11. Retrovirus vectors are generally not 
useful for neurological applications, as they cannot be used for gene transfer to 
non-dividing cells, such as neurons, although they can be used for lineage 
determination in embryos12, 13. While retroviral vectors have a modestly large 
packaging capacity (7-9 kb), they are produced at relatively poor titers and 
require proviral integration into the host genome for expression. The latter aspect 
is particularly concerning, as a trial for retroviral-mediated ex vivo gene therapy in 
children with X-linked severe combined immune deficiency (SCID) resulted in 
some patients developing leukemia as a result of activation of the LMO2 proto-
oncogene due to proviral integration14. However, SCID was cured by the 
treatment in all cases, and the few patients who developed leukemia were 
treated and survived15.  Several features of retrovirus integration, including 
tendency to integrate into promoter regions of genes combined with intact (long 
terminal repeat) LTR elements with enhancer activity in these early vectors has 
led to improvements in vector design1. 
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Lentiviral vectors derived from HIV-1 can mediate gene transfer to both dividing 
and non-dividing cells. Importantly, lentiviral vectors integrate preferentially in 
introns of transcriptionally active genes, and the use of self-inactivating designs 
that eliminate the promoter elements from LTRs in the provirus have reduced 
dramatically the oncogenic potential16, 17. Further, they can be pseudotyped with 
VSV-G (vesicular stomatitis virus G envelope protein) to allow purification to titers 
higher than MoMLV vectors, and have a similar transgene capacity as retroviral 
vectors. While lentiviral vectors can mediate long-term expression (years) in the 
non-human primate brain18, 19, their infection efficiency after direct injection is low. 
They have mainly been used for ex vivo gene therapy applications. A particularly 
successful example has been the halt of neurodegeneration in infants and 
children afflicted with X-linked ALD (X-ALD) and MLD in clinical trials involving 
transplantation of lentivirally-corrected autologous CD34+ hematopoietic cells3, 4. 
 
Adenoviral (Ad) vectors have some potential advantages over the 
abovementioned vectors: first, transgene packaging capacity can be up to 36 kb 
in high-capacity Ad vectors devoid of viral genes, albeit these “gutless” vectors 
are difficult to generate at high titers; second, the standard Ad vectors can be 
manufactured at titers up to 1,000-fold higher than retro- and lentiviral vectors; 
and third, the transgene does not integrate into the host genome and instead 
remains episomal, leading to stable and sustained expression in brain for at least 
up to a year20. Direct infusion into brain parenchyma results in gene transfer to a 
broad range of cell populations, including neurons, astrocytes, microglia, 
oligodendrocytes and ependymal cells21, 22.  A major limitation, however, is the 
strong innate immune response to the Ad capsid itself, as well as continuing low 
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level expression of viral genes in the standard vectors producing a secondary 
transgene/viral gene-dependent immune response, even after direct 
intraparenchymal infusion into the brain23. While this antigenicity facilitates their 
use as an immunogenic adjuvant, in vivo delivery at high doses can result in 
severe inflammation and cytotoxicity, which resulted in the death of a patient in 
an ornithine transcarbamylase (OTC) deficiency clinical trial24. Nevertheless, this 
continues to be a very popular vector, especially for clinical trials in cancer25. 
 
Herpes simplex viral (HSV) vectors can efficiently infect neurons and other cell 
types in vivo, and are capable of both anterograde and retrograde transport 
within neurons26, 27. This makes them attractive candidates for neurological gene 
therapy. HSV vectors can broadly be classified into two main categories: 
recombinant vectors, which have a packaging capacity of 50 kb, can be purified 
to high titers (up to 1011 particles per mL) and can persist as episomes post-
infection; and plasmid-based HSV amplicons, which have a capacity of up to 150 
kb, but are difficult to generate and can only be purified at 108 particles per mL28, 
29. Recombinant HSV vectors, in turn, can be sub-divided into replication-
competent and replication-defective vectors depending on whether they can 
undergo a lytic cycle, and both have found therapeutic use in a broad range of 
neurological disorders30. 
 
Adeno-associated virus (AAV) vectors are a relatively recent addition to this 
list of viral vectors, but have emerged as one of the most important ones for 
therapy of neurological disorders. It is currently the most frequently used viral 
vector for central nervous system (CNS) clinical trials (Table 1.1). AAV vectors 
are close to the ideal CNS gene therapy vector as they: a) can mediate gene   
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transfer to both mitotic and post-mitotic cells, albeit the transgene is lost over 
time in dividing cells; b) are neurotropic after direct infusion into brain 
parenchyma31; c) can exist stably in an episomal state with a low rate of genomic 
integration32; d) exhibit no pathogenicity or cytotoxicity; e) have very mild 
immunogenicity, mostly humoral33; and f) can be manufactured at high titers 
(1013-1014 particles per mL, depending on the production method) and at high 
purity34, 35. AAV vectors have been shown to mediate stable transgene 
expression in the human brain for >10 years36. However, a significant limitation of 
AAV vectors is their small packaging capacity (4.5 kb for single stranded vectors, 
2.4 kb for self-complementary vectors), which places severe limitations on the 
therapeutic cargo size. Recently, vexosomes, which are hybrid viral vectors 
comprising AAV associated with extracellular vesicles, have been shown to 
enhance considerably the gene transfer properties of AAV37, 38. 
 
Other viral vectors that infect neurons and thus can potentially be used for CNS 
gene therapy applications include RNA viruses, such as poliovirus replicon 
vector39, 40, Semliki Forest virus (SFV)41, 42 and Sindbis virus vectors43, as well as 
DNA viruses, such as SV4044, 45. 
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Modes and sites of delivery 
 
Within the context of delivery to the brain, virus vectors can be injected directly 
into regions of pathology using strategies that either limit or extend the range of 
transduction, or through intrathecal (IT), intraventricular, or intravascular routes. 
Of these, the intravascular route has historically been restrictive due to the blood-
brain-barrier (BBB), but new serotypes of AAV, modifications of AAV and 
hematopoietic stem cell-derived vehicles have now breached this barrier. 
 
Direct injection into brain parenchyma. Most clinical trials to date have 
investigated the therapeutic efficacy of direct neurosurgical infusion of virus 
vectors into the brain parenchyma. This approach bypasses the need to cross 
the BBB and works for well for AAV vectors. Among AAV serotypes, AAV2, the 
first discovered serotype, was used in all first generation clinical trials as it is 
highly neurotropic, but its distribution out from the injection site is relatively poor. 
Newer serotypes of AAV capsids discovered in the intervening years have 
dramatically improved transduction efficiency and volumetric spread. Different 
AAV serotypes have different preferential patterns of cell transduction. For 
example, while AAV1, AAV8 and AAV9 and AAVrh10 are primarily neurotropic46, 
AAV4 preferentially infects astrocytes and ependymal cells47, and AAV5 
transduces both astrocytes and neurons31. Part of this cell preference is probably 
due to differential binding of AAV serotypes to cell-surface receptors prior to 
internalization48-50. AAV9 and AAVrh10 are the leading candidates for 
intraparenchymal infusion, not only because of their vector spread but also 
because it can be transported along axons at high efficiency51, 52. 
Neurodegenerative disorders are often multifocal, affecting more than a single 
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structure in the CNS53. Therefore, global distribution of viral vectors, which is not 
limited to the site of injection, is desirable. Intracranial infusion of AAV vectors 
into axonally connected structures of the brain, such as the ventral tegmental 
area (VTA) or thalamus allows for widespread distribution of either AAV or 
encoded gene products that spread to distal projection sites by axonal transport51, 
54, 55. Use of pressurized convection-enhanced delivery (CED) and magnetic 
resonance imaging (MRI)-guided infusion can lead to significantly better 
distribution compared to single injections of smaller volumes56. Facilitated access 
across the BBB with AAV has also been achieved using focused ultrasound and 
microbubbles57. 
 
Infusion into cerebrospinal fluid (CSF). In addition to being spatially 
restricted58, intraparenchymal infusion is invasive and carries risk of surgery-
related side effects. To avoid these complications, an alternate less invasive 
route is administration into the CSF, where the viral vector can cross directly into 
the brain. This can be achieved by intracerebroventricular (ICV) or intrathecal (IT) 
injection of AAV vectors. Infusion into the lateral ventricles (ICV) in adult mice 
primarily results in transduction of the surrounding ependymal cell layer31, which 
can be extended to the brain parenchyma by intravenous co-administration of 
mannitol to raise osmolarity and thereby open up junctions between ependymal 
cells. ICV injection of AAV into neonatal mice provides a means of widespread 
gene delivery of many cell types throughout the brain and spinal cord59, 60. On the 
other hand, IT injection into the CSF, either at the subarachnoid space in the 
cisterna magna or into the intervertebral cistern in the lumbar spinal cord, is less 
invasive than ICV delivery and results in robust and widespread transduction of 
spinal cord motor neurons, as well as dorsal root ganglia (DRG) in mice61. In 
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higher species such as pigs and non-human primates, the spread of gene 
transfer after IT injection is much wider, with multiple cell populations (including 
neurons) in the brain and brainstem being transduced at high efficiency62-64. 
However, this route has some limitations. There are contradictory reports as to 
whether AAV administration via intra-CSF route shields against anti-AAV 
neutralizing antibodies64, 65. There is also some concern that the distribution 
results arise partly from AAV vector leaking from the subarachnoid CSF space 
into systemic circulation66. 
 
Delivery via the vasculature. Systemic administration has the potential to 
mediate gene transfer to the entire CNS ubiquitously and non-invasively with 
every cell in the brain being a maximum of 40 microns from endothelial cells67. 
AAV9 was the first AAV serotype to be shown to cross the BBB without 
pharmacological intervention68, and remains the gold standard for CNS therapy 
by intravenous delivery. Other serotypes, such as AAVrh8 and AAVrh10, were 
subsequently demonstrated to lead to robust and sustained CNS transduction 
following intravascular administration, transducing both neuronal and non-
neuronal cell populations69, 70. The mechanism of this BBB circumvention is not 
yet known. It is possible that such a mechanism might be serotype-specific, as 
exemplified by the observation that while transient opening of BBB tight junctions 
by mannitol leads to increased AAV2 CNS gene transfer71, 72, it does not enhance 
transport of AAV9 into the brain73. There are conflicting reports on the extent of 
neuronal transduction upon systemic administration in adults, possibly due to 
variations in dosage and promoter usage68, 74. Several concerns for clinical 
development exist. The first is significant vector loss and concerns of toxicity75 
due to high off target peripheral biodistribution, especially to the liver, which can 
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be somewhat reduced by restricting blood flow by occlusion76  or by choosing to 
express a therapeutic gene under a neuronal promoter. The other major concern 
is that the presence of neutralizing antibodies to AAV in monkeys and humans 
can severely limit the extent of gene transfer by systemic infusion65, 73. 
 
Age at time of infusion. The timing of AAV administration is one of the key 
factors that determine the extent of CNS transduction and the relative 
transduction of cell populations in the CNS. In general, transport across the BBB 
is higher in younger individuals77. Irrespective of the injection route, there are 
multiple reports suggesting that injection of AAV9 at P0 (post-natal day 0) in mice 
results in widespread neuronal transduction, while administration at older ages 
results primarily in glial and endothelial cell transduction, both with IV65, 68, 76 and 
ICV78 infusion. The switch away from neuronal transduction at older ages results 
in loss of therapeutic efficacy of AAV9-based approaches for some 
neurodegenerative diseases such as SMA where therapy is highly dependent on 
motor neuron transduction79. 
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Therapeutic modalities for neurological diseases 
 
a.  Gene replacement or inhibition 
Canavan disease (CD) is a pediatric leukodystrophy, characterized by 
accumulation of N-acetyl aspartate (NAA) in the brain due to mutations in the 
aspartoacylase (ASPA) gene80. CD gene therapy has historical significance, as 
the disorder represents both the first clinical trials for a neurodegenerative 
disorder (ICV administration of lipid-encapsulated plasmid DNA (LPD) containing 
hASPA cDNA81, and the first AAV-based FDA-approved clinical trial for a brain 
disorder82. This later Phase I/II clinical trial involved intraparenchymal infusion of 
AAV2-hASPA vector into the brain, and was based on pre-clinical proof-of-
principle studies on a transgenic rat model of CD83. No toxicity or long-term 
adverse effects were evident. Importantly, a significant decline in the elevated 
NAA levels was observed in the brains of all treated patients, albeit only modest 
neurological improvement was reported36. Although anti-capsid neutralizing 
antibodies could be detected, no correlation to clinical outcome was found. A 
recent preclinical study with intravenous delivery of AAV9 has shown seemingly 
complete phenotypic rescue of disease in a CD genetic mouse model84. 
 
Lysosomal storage disorders (LSDs) include over 50 rare individual genetic 
disorders resulting in defective metabolism and lysosomal accumulation, which 
collectively have a frequency of one per 7000-8000 live births85. Enzyme 
replacement therapy is the most common clinical treatment for this group of 
disorders, but is less effective for the neurological symptoms due to the inability 
of the enzymes to cross the BBB. LSDs are a good target for gene replacement 
therapy, as correction of even 5-10% of normal enzyme levels is enough to stop 
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disease progression, and genetically modified cells can cross-correct neighboring 
cells through enzyme secretion and uptake by the mannose-6-phosphate 
receptor pathway86. A Phase I/II clinical trial for MLD involving transplantation of 
autologous hematopoietic stem cells corrected ex vivo with a lentiviral vector 
expressing functional arylsulfatase A (ARSA) enzyme, reported stable ARSA 
gene replacement, no aberrant clonal cell expansion and no manifestation of 
disease 7-21 months after the predicted disease onset3. Gene therapy for LSDs 
involving in vivo AAV gene replacement have been successful in preclinical 
models, but less so in clinical trials. Numerous pre-clinical studies with gene 
replacement by in vivo intracranial AAV administration have shown partial to 
complete phenotypic correction in animal models of several LSDs. These include 
MPS I87, MPS IIIA88, MPS IIIB89, 90, MPS VII51, MLD91, 92, multiple sulfatase 
deficiency (MSD)93, Niemann-Pick A disease94, Pompe disease95, GM1-
gangliosidosis96, Tay Sachs disease97 and Sandhoff disease98. 
 
On the other hand, clinical trials have proved less effective. While intracranial 
administration of an AAV2-CLN2 vector in late-infantile Batten disease (late-
infantile neuronal ceroid lipofuscinosis, LINCL) patients in a Phase I/II clinical trial 
was found to be safe, there was no significant clinical improvement99. Similar 
results were found in a Phase I/II trial for Sanfilippo syndrome type A 
(mucopolysaccharidosis IIIA, MPS IIIA), where intracranial administration of 
AAVrh10-SGSH-SUMF1 vector was well tolerated in the patients, but resulted in 
only minor improvement in clinical outcomes100. Other clinical trials for LINCL 
(NCT01414985) and MPS IIIA (NCT02053064) based on the above two studies 
have been initiated. Clinical trials for Pompe disease (NCT02240407, 
NCT00976352), MLD (NCT01801709), giant axonal neuropathy (GAN) 
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(NCT02362438) and a proposed trial for MPS IIIB, all based on gene 
replacement in vivo by AAV vectors, are currently being initiated. The modest 
outcomes in human trials may be related to the doses that have been tested 
which have yet to reach doses successfully tested in animal models. In addition 
the choice of delivery routes and target sites/structures which are effective to 
treat a small mouse brain may not be adequate to achieve widespread 
distribution of functional enzyme in the ~2,000-fold larger human brain. 
 
X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 
gene, which results in the accumulation of very long-chain fatty acids (VLCFA) in 
the body. The cerebral form of the disease is fatal. Hematopoietic stem cell 
transplantation of CD34+ cells corrected ex vivo by a lentiviral vector encoding 
ABCD1 gene into two X-ALD patients with cerebral demyelination resulted in 
reversal of demyelination and alleviation of associated neurological symptoms in 
both patients4. Further, no clonal cell expansion or preference for oncogenic site 
of genome integration could be detected, highlighting the safety profile of such a 
therapy. A recent preclinical study in Abcd1 knock-out mice showed that in vivo 
delivery of AAV9-ABCD1 could reduce VLCFA levels in the CNS101. 
 
Spinal muscular atrophy (SMA) is a fatal infantile motor neuron disorder, 
resulting from loss of the SMN1 gene. Gene replacement by intravascular AAV9 
administration has proved effective in preclinical studies in both mice and non-
human primates79, 102-105. Based on these studies, a Phase I clinical trial 
(NCT02122952) with intravenous administration of AAV9-SMN1 has been 
initiated in babies 2-9 months of age. 
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Other disorders. Pre-clinical in vivo AAV gene therapy studies have been 
carried out for several other disorders involving both gene replacement in 
recessive disorders or inactivation of mutant genes in dominant disorders. These 
include Rett syndrome (delivery of MeCP2106), amyotrophic lateral sclerosis 
(ALS) (shRNA targeting SOD1107; delivery of ADAR2108; delivery of single chain 
antibody targeting misfolded SOD1109), Huntington’s disease (shRNA targeting 
HTT110; artificial miRNA targeting HTT111, 112) and Machado-Joseph disease 
(artificial miRNA targeting ATXN3113). 
 
b. Trophic factor support and neurotransmitter modulation  
Parkinson’s disease and AADC deficiency. Parkinson’s disease (PD) is an 
age-related neurodegenerative disorder that affects about one in every 100 
people older than 60 years of age worldwide, and as many as one million people 
in the United States alone. PD is characterized by the loss of dopaminergic 
neurons in the substantia nigra with resulting loss of dopamine in the putamen114. 
The current standard of care involves dopamine replacement by administration of 
levodopa and deep brain stimulation; however, levodopa becomes ineffective in 
advanced stages of the disease, probably because of the continuing loss of 
dopaminergic neurons. 
 
Clinical intervention for PD by intraparenchymal delivery of viral vectors can 
broadly be divided into two strategies: overexpression of enzymes involved in 
neurotransmitter synthesis; and overexpression of neurotrophic factors that can 
promote neuron survival. One clinical trial was based on the first approach, 
where AAV2 encoding glutamic acid decarboxylase (GAD) was injected into the 
subthalamic nucleus of PD patients to generate the inhibitory transmitter gamma 
  
19 
amino-butyric acid (GABA115), which satisfied the Phase I safety criteria. 
However, a Phase II clinical trial, resulting from the findings of this study, showed 
only modest efficacy116. Infusion of AAV encoding aromatic L-amino acid 
decarboxylase (AADC), which converts L-dopa to dopamine, into the putamen 
was also shown to be safely tolerated in two Phase I clinical trials117, 118. While 
long-term stable AADC expression could be detected by PET scanning, the initial 
clinical improvement deteriorated over 4 years even with continued 
administration of L-dopa119. A new Phase I trial based on combined pressurized 
CED and MRI-guided infusion into the putamen is currently recruiting participants. 
A Phase I/II dose escalation study involving infusion of ProSavin, a tricistronic 
self-inactivating lentiviral vector encoding tyrosine hydroxylase (TH; the first and 
rate limiting enzyme in dopamine synthesis), AADC and GTP cyclohydrolase I 
(GCH1; which generates the biopterin cofactor for TH) was found to be well 
tolerated with no toxicity, and even showed improvement in motor function in 
combination with L-dopa administration in patients injected at the higher dose120. 
These interventions to alter firing patterns or increase dopamine levels in the 
brain have to be seen in the context of degeneration of dopaminergic neurons, 
which continues unabated. 
 
The second approach is based on the expression of neurotrophic growth factors. 
The prime example is neurturin (NRTN), a natural analog of glia-derived 
neurotropic factor (GDNF), which has been shown to protect dopaminergic 
neurons in pre-clinical studies121-123. Again, while Phase I clinical trials with 
CERE-120 AAV2-NRTN vectors showed no adverse effects124, Phase II efficacy 
results were modest with no significant improvement in primary outcome 
measure at 1 year, albeit with some improvement at a later time125. Injection into 
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both putamen and substantia nigra in a Phase IIb clinical trial did not improve this 
disappointing clinical outcome126. A third emerging approach is to decrease 
levels of alpha-synuclein expression, which accumulates in the brains of PD 
patients, using an AAV vector encoding a short hairpin (sh) RNA targeting the 
mRNA for this protein127, which has yet to be tested in patients. 
 
While AAV2-AADC delivery to the putamen resulted in modest clinical outcomes 
in PD patients, a similar strategy used in a Phase I study to treat AADC 
deficiency (a fatal loss-of-function disorder with a high prevalence in Taiwan) 
showed highly promising results128. Treated children that are otherwise unable to 
move showed improved motor function and increased dopamine in the CSF, with 
no AAV-associated toxicity. This may have implications for PD therapy, as it 
could indicate that clinical intervention may become less effective at a later age. 
 
c.  Compensatory proteins  
Alzheimer’s disease (AD) is one of the main causes of dementia in the elderly, 
affecting 6% of individuals 65 years and older129. The vast majority of patients 
suffer from the sporadic form of the disease, but numerous predisposing genes130, 
as well as environmental risk factors, such as traumatic brain injury131, 
diabetes132, stroke and hypertension133 have been identified over the years. The 
defining neuropathologic characteristics are accumulation of Aβ peptide, a 
cleaved product of amyloid precursor protein (APP), in toxic amyloid fibrils 
forming extracellular plaques, in association with abnormally 
hyperphosphorylated tau filaments composing intraneuronal neurofibrillary 
tangles.  These hallmarks are associated with elevated levels of inflammatory 
cytokines, including interleukin1β and TNFα, disregulated calcium homeostasis, 
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synapse collapse, neuronal dysfunction and death (especially of cholinergic 
neurons134.  The multiple etiologies of this disease make it hard to identify a 
therapeutic target, although the consensus seems to be that decreasing levels of 
Aβ peptides and/or preventing abnormal tau phosphorylation and aggregation is 
an important goal. 
 
The devastating consequences of this disease have elicited a broad range of 
gene therapy strategies135 with only a recent subset listed below. The most 
straightforward strategies have aimed at directly inhibiting the production of 
neurotoxic species of amyloid, either via viral vector expression of Aβ degrading 
enzymes, such as Neprilysin136, 137, or anti-Aβ single-chain antibodies to achieve 
passive immunization138. Alternatively, targeting the cleavage of APP has been 
attempted, with genetic transfer of siRNA specific for β-secretase139 or shRNA to 
knock-down the orphan G protein-coupled receptor that regulates activity of γ-
secretase140, the first and second enzymes, respectively, controlling the 
proteolysis of APP to produce the neurotoxic amyloid peptides, respectively. 
Additionally, AAV-mediated expression of CD74, a chaperone that directly binds 
to the APP, also prevents the accumulation of Aβ in the hippocampus and 
improves cognitive deficits of AD mice141. 
 
Because of the complexity of the molecular mechanisms underlying AD 
neuropathological changes and the relatively low success of therapeutic 
strategies directly based on the “amyloid hypothesis” in clinical trials, other 
alternative approaches have emerged. Based on genetic risk studies, it was 
found that individuals who inherit the rare apolipoprotein E (APOE) ε2 allele have 
a markedly reduced risk of developing AD by about 50%. Expressing this specific 
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isoform of APOE in the brains of a mouse model of AD after ICV infusion of an 
AAV4 vector reduced amyloid plaque formation and associated synapse loss142. 
Potentially, viral vectors could also be used to express anti-ApoE antibodies, an 
alternative immunotherapy approach that has proven effective in AD mouse 
models143. Recently, silencing expression of acylCoA-cholesterol acyltransferase, 
an important enzyme regulating lipid metabolism, as well as APP processing, 
using a vector encoding an artificial miRNA was shown to alleviate both amyloid 
and tau pathology in a transgenic AD mouse model144. Finally, hippocampal 
delivery of an AAV vector encoding cholesterol-24S-hydroxylase, an enzyme that 
regulates neuronal cholesterol efflux, ameliorated cognitive deficits and spine 
defects associated with a murine model of tauopathy without impacting Tau 
hyperphosphorylation145. This approach was also shown to reduce dramatically 
the Aβ burden and neuropathology in the brain of APP23 mice146. 
 
Other therapeutic approaches to AD gene therapy are more tangential, including 
AAV delivery of a FK506-binding protein (FKBP1b) that stabilizes Ca++ release 
from the endoplasmic reticulum in neurons147 or delivery of growth factors that 
help neurons survive toxic injury, including delivery of cerebral dopamine 
neurotrophic factor (CDNF)148, insulin growth factor149, brain-derived neurotrophic 
factor (BDNF)150 and nerve growth factor (NGF)151 to the brain using different 
virus vectors. The latter has proceeded to promising clinical trials. 
 
d.  Potential for genome engineering in vivo 
While lentiviral vectors have been used as the vector of choice for ex vivo gene 
transfer4, AAV vectors are emerging as the leading delivery vehicle for in vivo 
gene transfer, including for genetic engineering. This is largely due to high 
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efficiency gene delivery to a large number of tissues including brain, excellent 
long-term safety profile in clinical trials152, 153, and low rates (~0.1%) of random 
chromosomal integration32. This last point may be somewhat controversial, as 
there may be some concerns of integration ‘hotspots’, particularly in unstable154, 
155 and transcriptionally active regions of the genome156. Most studies on AAV 
mediated genome editing have been based on homologous recombination (HR) 
between AAV-encoded transgenes and a specific chromosomal locus157. The 
transgene typically contains genomic sequences flanking the locus, allowing site-
specific insertion via the canonical HR pathway. While the majority of the work 
using this method has been done in vitro to create modified cell lines158, 159, there 
have been several in vivo studies. These include correction of β glucuronidase 
for mucopolysaccharidosis VII160, fumarylacetoacetate hydrolase (Fah) for 
hereditary tyrosinemia161, and factor IX (FIX) for hemophilia B162. The FIX study 
used a promoter-less editing strategy, relying on insertion of the transgene into 
the transcriptional unit of the albumin locus, which increases the safety of this 
approach162. However, the frequency of gene correction observed in these 
studies was extremely low (fraction of corrected cells ranging from 10-4 to 10-2). 
This frequency may be too low for clinical applications outside the liver, 
particularly in the CNS. 
 
The field of genome engineering has been revolutionized by the discovery of 
targeted nucleases. These include zinc-finger nucleases (ZFNs), TALENS, and 
most recently CRISPR-Cas9163. These methods allow creation of site-specific 
double strand breaks in the genome, allowing for either disruption of gene 
function, or gene correction by homology repair at those sites using a normal 
oligonucleotide spanning the mutation. Therapeutic benefit from AAV-mediated in 
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vivo genome editing has been demonstrated in both neonatal164  and adult165 
mouse models of hemophilia B, as well as in a mouse model of Huntington’s 
disease166. Genome editing by CRISPR-Cas9 represents the most recent 
advance in this field, and this technology has found use in many fields including 
generation of mouse models of human disease, cancer biology, drug 
development, etc167. AAV-mediated genome editing using CRISPR-Cas9 has 
been shown to be effective in liver168 and more crucially in the context of 
neurological disorders, in brain7. Co-injection of two AAV vectors encoding 
SpCas9 and sgRNAs targeting the Mecp2 gene (mutated in Rett syndrome) into 
the visual cortex of mice resulted in effective gene editing at this locus and a 
resulting electrophysiological response7. Limitations of such therapy include the 
relatively large size of SpCas9 relative to the transgene capacity of AAV (hence 
the need for two vectors), the potential antigenic nature of this bacterial protein, 
and off-target effects in the genome that might accumulate with long-term 
expression of these transgenes. The first can be resolved by using shorter Cas9 
from other bacterial species168. Non-Cas9 CRISPR effectors are also being 
developed169. Overall, this is a very promising field that is likely to foster the next 
generation of CNS gene therapy. 
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The AAV capsid 
 
AAV is a parvovirus of the genus Dependovirus, classified thus because AAV 
depends on co-infection of an unrelated helper virus (adenovirus or herpesvirus) 
for productive infection. The AAV virion consists of a non-enveloped icosahedral 
capsid and an encapsidated 4.7-kilobase (kB) single-stranded DNA viral 
genome170. For wild-type AAV (wtAAV), this genome comprises of two open 
reading frames (ORFs), rep and cap, flanked by two inverted terminal repeats 
(ITRs)171 (Figure 1.1). The rep ORF encodes four overlapping proteins: Rep78, 
Rep68, Rep52 and Rep40, which play crucial roles in AAV replication and 
packaging. DNA replication depends on the two larger proteins (Rep78 and 
Rep68), which have single-strand endonuclease, DNA helicase and ATPase 
activity, while the two smaller proteins (Rep52 and Rep40) are required for AAV 
packaging and only have helicase activity. Expression of these four proteins is 
initiated from the p5 and p19 promoters. The p40 promoter, present on the rep 
ORF, initiates transcription of two alternatively spliced mRNAs from the cap ORF 
that encode three capsid viral proteins (VPs): VP1, VP2 and VP3, and an 
assembly activating protein (AAP). The larger of these mRNAs encodes for VP1 
and comprises the entire cap ORF, while the other mRNA is smaller and 
encodes for VP2 and AAP from weak non-canonical start codons (ACG and CTG, 
respectively), and VP3 from a conventional downstream ATG start codon. The 
capsid proteins VP1 (87 kDa), VP2 (73 kDa) and VP3 (61 kDa) assemble in a 
ratio of ~1:1:10 to yield the AAV capsid with a diameter of ~20 nm. The 145-bp 
ITRs form stable T-shaped hairpin structures at either end of the genome and 
function as start sites of DNA replication and play a key role in viral genome 
integration.  
  
26 
 
 
 
Figure 1.1: Map of wild type AAV genome. The ~4.7 kB genome contains two 
ORFs, rep and cap. The rep ORF (blue) codes for four Rep proteins: Rep78, 
Rep68, Rep52 and Rep40. These play crucial roles in AAV DNA replication and 
packaging. The cap ORF (yellow) codes for three capsid proteins: VP1, VP2 and 
VP3. These assemble in ~1:1:10 ratio to form the AAV capsid. The VP3 protein 
forms the capsid shell, while VP1 and VP2 are thought to be in the interior of the 
capsid. In addition, the cap ORF also codes for assembly activating protein 
(AAP) that promotes assembly and maturation of the capsid, but is not present in 
the capsid. The rep and cap ORFs are flanked by inverted terminal repeats 
(ITRs) that are start sites of replication and also play a role in integration into host 
genome.  
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The ITRs are the only necessary cis elements in the viral genome. Recombinant 
AAVs (also commonly known as AAV vectors or rAAV) used for gene delivery 
approaches are generated by replacing the viral genes with a transgene cassette 
while retaining the ITRs in cis. Rep and cap genes are supplied in trans during 
vector production, along with adenoviral helper genes. Properties of such 
resulting vectors have been listed in previous sections.  
 
AAV capsid structure 
Discovered 50 years ago as a contaminant in adenoviral stocks172, 173, 12 distinct 
AAV serotypes (AAV1 – 12) have been identified from human and non-human 
primate (NHP) to date174-178. Based on serologic cross-reactivity and amino acid 
sequence, these can be broadly divided into 8 clades174: A-F and isolates AAV4 
and AAV5 (on account of the divergence of these two serotypes from the others), 
with the clades sharing varying levels of sequence homology (60-99%) with each 
other. Numerous variants within each clade have been isolated. Elucidation of 
crystal structures of representative members of all the antigenic clades (AAV1179, 
AAV2180, AAV3B181, AAV4182, AAV5183, AAV6184, AAV7185, AAV8186, AAV9187) as 
well as of AAVrh8188 (not part of the major clades) and the modified capsids 
AAVrh32.33189 and AAV-DJ190, has helped correlate some of the structural 
elements with associated capsid functions.  
 
The VP monomers assemble in the host nucleus to form the T=1 icosahedral 
capsid with two-, three- and five-fold axes of symmetry191. These symmetry 
interactions create characteristic topological features on the assembled AAV 
capsid: depressions at the two-fold axes, protrusions and depressions at the 
three-fold axes, and channels at the five-fold axes. The AAV capsid is comprised 
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of 8 highly conserved β-sheets (βB-βI), arranged as a “jelly-roll” β-barrel and form 
the contiguous shell of the capsid, and a highly conserved α-helix (αA). 
Conversely, surface exposed loops (located between the β-strands) differ in their 
amino acid composition across serotypes. These loops form most of the outer 
surface of the capsid, and play critical roles in transduction, receptor binding and 
antigenic response. Nine such clustered loops (VR-I to –IX; variable region) exist, 
and most serotypes differ in one or more of these loops. However, it is difficult to 
predict the properties of any particular serotype by the surface topology alone.  
 
The published structures, for AAV or any parvovirus, are determined only for the 
overlapping C-terminus sequence, i.e. VP3. The N-terminal sequences (unique 
VP1 N-terminus, i.e. VP1u, and VP2 N-terminus) are thought to be 
“disordered”180 and experimental evidence suggests they are located in the 
interior of the capsid (according to cryo-EM studies of empty capsids)192. The 
cause of this “disorder” is not clear so far. The requirement of VP1 and VP2 for 
capsid formation is controversial, with conflicting reports on whether VP3 alone is 
sufficient for capsid assembly193-197. It is generally agreed that the nuclear 
localization signal195 and AAP198, both located upstream of VP3 ORF, are 
required along with VP3 for successful formation of virus-like particles (VLPs). 
 
Role of capsid in AAV life cycle 
The role of the capsid is not only limited to protecting the encapsidated 
genome/transgene, but includes mediating such essential functions as host cell 
recognition and receptor binding, endosomal entry and trafficking, and nuclear 
entry (Figure 1.2). Information for receptor recognition is available for several  
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Figure 1.2: AAV vector entry into cells. Receptor footprints on the surface of 
AAV capsids vary with serotype, which allows them to bind to a variety of glycan 
receptors on the host cell surface (HSPG, N- and O-linked sialic acids, 
galactose). Once bound, the virion gets internalized via clathrin-coated vesicles 
and trafficked to the nuclear area while encapsulated in an endosome. 
Endosomal acidification leads to release of the virion, which is transported into 
the nucleus. Capsid uncoating in the nucleus is followed by conversion of the 
single-stranded vector genome to double-stranded DNA. In case of AAV vectors, 
the double-stranded vector genome persists as stable circular and concatemeric 
extrachromosomal episomes.  
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serotypes; however, much of the data on subsequent steps has only been 
elucidated for AAV2, the most studied AAV serotype.  
 
Binding to cell surface receptors: After multiple cell surface contact events199, 
the essential first step of the AAV infection cycle is attachment to a host cell 
surface receptor. These glycan receptors vary with serotype48, 200-205, and choice 
of receptor is the primary determinant of cell transduction properties for a 
particular serotype. Subsequent interaction of the AAV capsid with co-receptors 
stabilizes the low-affinity binding to the primary receptor. AAV clades can be re-
organized into 3 major groups, according to their primary receptor preference: 
those binding to (a) heparan sulfate proteoglycan (HSPG): AAV2201, AAV3202 and 
AAV6206; (b) sialic acid: AAV1200, AAV448, AAV548, 203 and AAV6200; and (the most 
recently discovered) (c) galactose: AAV950, 205. Primary glycan receptors for 
AAV7 and AAV8 are not yet known. While most clades show a clear preference 
for one or the other of these 3 receptors, AAV6 can bind to either HSPG or N-
linked sialic acid. A list of primary receptors and co-receptors for each serotype is 
provided in Table 1.2. It is important to note that irrespective of serotype, 
receptor-binding sites map near the protrusions surrounding the icosahedral 
three-fold axes of symmetry48, 180, 204, 207. This region of the capsid is therefore the 
primary structural determinant of receptor recognition, possibly providing the first 
indication of how AAV structure has evolved to generate phenotypic variability 
across clades. 
 
Internalization: Binding to the primary receptor induces a structural 
rearrangement of the capsid, required for subsequent internalization208. The 
process of internalization is dependent on the co-receptors. Growth factor  
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receptors209-211 and laminin receptor212 are thought to facilitate capsid structural 
rearrangement and increase the affinity of the capsid to the host cell. Integrins208, 
213, 214 likely induce cytoskeletal rearrangements in the host cell and thus play a 
role in endocytosis of the virion. AAV2 is internalized by either dynamin-
dependent clathrin-coated pit pathway215, 216, and/or by a recently elucidated 
clathrin- and dynamin-independent CLIC/GEEC pathway217. Other AAVs may 
use different internalization pathways218. Motifs on the AAV2 capsid surface that 
interact with the co-receptors have been identified208, 213, and are again localized 
near the base of the three-fold protrusions, but are only partially surface-exposed.  
 
Endosomal trafficking and release: AAV2 appears to localize in both late 
(Rab7) and recycling (Rab11) endosomes, although trafficking via the Rab11 
pathway leads to higher AAV transduction219. Endosomal acidification triggers 
conformational changes in the viral capsid (possibly by selective cleavage of 
capsid proteins by acid-dependent endosomal proteases)216. This causes the 
phospholipase A2 (PLA2) domain located in VP1u to become surface-exposed192, 
likely through the five-fold channel, which leads to escape of the virion from the 
endosomal compartment through an unknown mechanism. 
 
Cytoplasmic processing: After the virion is released from the endosomal 
compartment, further processing in the cytoplasm occurs prior to nuclear entry. 
This includes the capsid being phosphorylated and then ubiquitinated, tagging 
the capsid for proteasomal degradation220-222. Mutation of capsid surface 
tyrosines, thought to be sites of phosphorylation, decreases proteasomal 
degradation and in turn, enhances transduction220, 221. 
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Movement through cytoplasm and across nuclear membrane: The AAV 
virion moves through the cytoplasm to the perinuclear region along a microtubule 
network223, 224, although this may not be the only mechanism of motility as free 
diffusion in the cytoplasm has also been reported199. The mechanism of transport 
across the nuclear membrane is even less understood, although putative nuclear 
localization signals in the VP1/VP2 N-termini are accessible on the capsid 
surface at this stage and are thought to play a role in nuclear transport activity216, 
225. Whether the transport occurs through the nuclear pore complex, or through 
an unidentified pathway involving perforation of the nuclear membrane is 
unclear226-228. 
 
Capsid uncoating and genome release: It is generally agreed that capsid 
uncoating occurs in the nucleus214, 216, 226, 229 allowing for release of the ssDNA 
viral genome, although some contradictory evidence suggests that it could occur 
in the perinuclear region prior to nuclear entry215. While the mechanism of this 
uncoating process is unknown, a putative CDK2/cyclin A kinase binding motif in 
the VP1/VP2 N-termini has been implicated230.  
 
Subsequent steps: Once released, the ssDNA viral genome converts to the 
double stranded (ds) form. In the absence of helper virus, rep-containing wild 
type AAV enters a latent cycle by integrating into the host genome preferentially 
at the AAVS1 locus on chromosome 19 in human231, 232. This process involves 
the Rep proteins binding both the viral genome at the ITRs and a homologous 
sequence at the AAVS1 locus233-235. Infection by helper virus can “rescue” this 
integrated genome to package progeny AAV particles, by inducing replication 
and gene expression of the viral proteins. The AAV capsid is not known to play a 
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role in the steps post genome release and prior to capsid assembly and genome 
encapsidation.  
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Re-engineering the AAV capsid 
 
AAV is close to the ideal gene therapy vector, due to their ability to mediate long-
term gene expression in vivo, and their excellent safety profile in several clinical 
trials152, 153, 236. However, specific applications require improved versions of the 
AAV capsids isolated from human and NHP samples. Properties of capsids 
derived from natural AAV isolates have been altered to improve their biological 
properties, such as tropism and transduction efficiency, to re-direct to non-natural 
receptors, or to shield from host immune responses. Re-engineering of the 
discrete surface-exposed variable loops (and other regions, in some cases) has 
been achieved by several techniques to yield novel AAV capsids. These 
techniques can be broadly divided into 5 major classes: 1) genetic grafting of 
peptides onto the capsid surface to re-direct tropism, 2) generating hybrid or 
chimeric capsids derived from cap genes of two serotypes, in order to combine 
properties of both into a single vector, 3) rational mutagenesis of a natural AAV 
isolate, based on structural information of the capsid, 4) chemical or non-
genetic conjugation of receptor-binding or masking moieties directly onto the 
surface of a fully assembled virion, and 5) biopanning from a library of chimeric 
AAV capsids to isolate a unique variant with a desired phenotype. Some select 
re-engineered capsids and their properties have been tabulated in Table 1.3. 
 
Genetic grafting of peptides  
A natural AAV capsid can be re-targeted by (ideally) eliminating the interaction 
with its native receptor and grafting a peptide onto the capsid surface that can re-
direct the capsid to bind to an alternate receptor. The earliest approaches tried to 
identify suitable sites on the AAV capsid for peptide insertion. Sites were chosen 
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where insertion does not drastically decrease capsid assembly and vector 
packaging yield, while ensuring that the inserted peptide be presented on the 
surface of the capsid to be able to demonstrate biological activity. Scanning 
mutagenesis across the AAV2 cap gene has yielded several such promising 
sites197, 225. Two positions that have been primarily used are 1) at amino acid 
positions 138 and 139 (in the VP1/VP2 N-terminus)196, 225, 238, 239, 251, 252, and 2) at 
positions 587 and 588 (in the common VP3 C-terminus)237, 253-263. Insertions at 
the first locus are expressed fused only to the VP1 and VP2 capsid proteins196, 
and thus have a low copy number in the virion, compared to insertions at the 
latter locus, which is expressed in every monomer. While the VP1/VP2 N-
terminus is conventionally thought to be expressed in the interior of the capsid192 
and thus is not surface-exposed, there is evidence that genetic insertion at that 
locus allows for exposure of the exogenous peptide on the capsid surface196, 238, 
239, perhaps mimicking the escape of VP1/VP2 N-terminus and exposure of PLA2 
domain during endosomal escape. However, depending on the peptide size, 
insertions at this location marginally251 or drastically196 reduces VP3 expression. 
While providing VP3 in trans restores capsid assembly, vector yields and 
infectivity can remain lower than the unmodified capsid196. In addition, the 
modified capsid still retains its natural tropism, which can lead to significant off-
targeting in vivo. This appears to be (at least) in part due to the presence of 
capsids containing only VP1 and VP3, and thus on-target specificity can be 
improved by selecting capsids that incorporate VP2239. Insertion at the 587/588 
site, on the other hand, can directly interfere with AAV2 binding to HSPG264, thus 
ablating natural tropism in some insertion vectors253, 255-257 and increasing 
likelihood of being re-directed to the desired non-HSPG receptor. The peptides 
screened thus far primarily at these two loci have not only been those with known 
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receptor binding properties, but also those identified through biopanning of 
peptide libraries and thus with unknown host receptors237, 263. Peptides are not 
required to be short, and can be as large as full-length proteins196, 265, depending 
on the site of insertion. Several re-targeted novel capsids have been generated 
by this technique, including those with increased in vivo gene transfer to vascular 
tissue260, 262, disease-altered brain vascular endothelia237, lung266, 267, skeletal268, 
269 and cardiac270 muscle, lymphocytes239, retina (by intravitreal injection)248 and 
several types of implanted tumor cells238, 239, 254, 267.  
 
Hybrid/chimeric capsids  
Initial efforts were directed at producing mosaic capsids, which could (in theory) 
combine the phenotypic properties of different serotypes. Mosaic capsids 
containing VP monomers from two or more different serotypes in a single virion 
are generated by co-transfecting cap genes of the serotypes during viral 
production. Examples of successful mosaic capsids include an AAV1/2 hybrid 
that combined the HSPG mediated gene transfer to liver of AAV2 with the muscle 
tropism of AAV1271, and an AAV3/5 hybrid that can bind both HSPG (like AAV3) 
and mucin (like AAV5)272. Deeper understanding of capsid structure-function 
relationship and in particular, knowledge of receptor “footprints” of particular 
serotypes has allowed for more precise attempts at producing hybrid capsids. 
Prominent examples are AAV2i8243, an AAV2/8 hybrid created by replacing six 
amino acids on AAV2 capsid responsible for HSPG binding with corresponding 
AAV8 residues; and AAV2.5244, an AAV2/1 hybrid created by replacing five 
amino acids on AAV2 capsid with corresponding AAV1 amino acid residues 
responsible for skeletal muscle tropism. The former displayed improved muscle 
tropism combined with reduced hepatic tropism, while the latter demonstrated 
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enhanced muscle transduction while preserving HSPG binding, and was used in 
a Phase I clinical trial for Duchenne muscular dystrophy. Rational grafting of 
galactose-binding footprint of AAV9 generated AAV2G9, an AAV2/9 hybrid with 
dual binding capacity to galactose and heparin receptors, and AAV2i8G9, an 
AAV2i8/9 hybrid with muscle gene transfer efficiency comparable to AAV9 while 
retaining the reduced liver tropism of AAV2i8273. Other examples include AAV2/1 
hybrid with reduced sensitivity to AAV2-specific neutralization274, AAV1/6 
hybrids206 and even an AAV2/canine parvovirus hybrid275. 
 
Rational (structure-guided) mutagenesis  
Improved understanding of AAV structure has allowed for not only precise hybrid 
capsid engineering, but also mutation or substitutions of specific amino acids 
responsible for a certain vector function. Several liver de-targeted (such as 
AAV9.45) and liver- and muscle-detargeted mutants (such as AAV9.47) have 
been generated by mutagenesis of AAV9 along the surface-exposed three-fold 
axes245. AAV6.2, a single amino acid mutant of AAV6, displayed superior gene 
transfer to airway epithelium240, 276. Identification of antibody recognition motifs on 
the capsid surface has led to development of AAV2 mutants with a reduced 
neutralization profile while retaining other properties277, 278. A prime example of 
structure-guided mutagenesis is the generation of AAV2-based capsids where 
surface-exposed tyrosines, serines and threonines are mutated221. As mentioned 
in an earlier section, these residues on the capsid surface are thought to act as 
sites of phosphorylation during cytoplasmic processing following cell entry, 
leading to ubiquitination and subsequent proteosomal degradation of capsid220-222. 
Tyrosine, serine or threonine mutants display enhanced transduction efficiency of 
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various cell populations in vivo in mice221, 279-283 and dogs284, 285, although whether 
this effect extends to other serotypes such as AAV8 and AAV9 is controversial286.  
 
Chemical conjugation  
Coating the AAV capsid surface can physically prevent the virion from interacting 
with its native receptors and can also shield it from neutralizing antibodies. This 
can be achieved by chemical conjugation of the capsid to various polymers such 
as polyethylene glycol (PEG)287 and poly-[N-(2-hydroxypropyl) methacrylamide] 
(HPMA)288, and selective masking of surface-exposed arginine residues by 
glycation using α-carbonyl compounds289. Conjugation of bioactive molecules 
such as antibodies specific to αIIbβ3 integrin290, or EGF291 can further enhance 
transduction to target cells overexpressing the respective receptors. However, 
this approach to capsid engineering has had scant success in vivo.  
 
Library biopanning  
While most of the above approaches demand at least partial understanding of 
the transduction process, biopanning does not require any such prior mechanistic 
insight. This high throughput approach instead applies a screening process to 
enrich for capsids with a particular biological property from an initial pool. This 
process therefore, imitates natural evolution with the exception that all genomic 
variants are present simultaneously in the starting pool, which allows for 
scanning through a large pool of capsid variants in one (library selection) or a few 
(directed evolution) cycles, rather than the geologic timescales of natural 
evolution. For directed evolution, after each cycle, the selected variants are 
rescued (either by helper virus infection or PCR amplification), diversified further 
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by additional mutagenesis, and used as the starting material for the next cycle of 
selection. Starting libraries can be created by subjecting natural AAV isolates to 
one of two processes: 1) error-prone PCR292, 293 which introduces nucleotide 
substitutions across the cap of a particular serotype, or 2) DNA shuffling246, 294, 295, 
where cap genes of several serotypes are fragmented by nuclease digestion and 
randomly re-assembled by PCR to produce chimeric genomes. Care must be 
taken to ensure capsid-genome correlation during encapsidation of the chimeric 
genomes, although a recent study has suggested that production of the virus-like 
AAV libraries naturally result in very low cross-packaging296. Directed evolution 
has been particularly successful in vitro, yielding capsid variants capable of 
selective and enhanced transduction of a variety of cell types297-300, with the 
particular examples of adult and pluripotent stem cells301-303 which are typically 
refractory to AAV transduction. Several variants capable of evading neutralizing 
antibodies present in the human sera have also been isolated by this 
technique246, 292-295, 304. This is particularly relevant in the clinical setting where a 
majority of the human population has a high prevalence of neutralizing antibodies 
to natural AAV isolates242, 305, thus posing a critical challenge for intrahepatic and 
intravenous AAV administration306, 307. Success in vivo has been comparatively 
limited, with only a few studies succeeding in selecting novel capsid variants 
capable of targeting cardiomyocytes247, transducing Müller cells in the retina 
through intravitreal injection308, crossing the seizure-compromised blood-brain 
barrier309, transducing photoreceptors from the vitreous humor248, or targeting 
xenotransplanted human hepatocytes249. Next generation sequencing has 
allowed the simultaneous characterization of hundreds of capsids variants, 
providing insight into several capsid functions310, 311. 
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In addition to the above techniques, a novel approach to identify putative 
ancestral AAVs by in silico reconstruction has yielded vectors with broad in vivo 
gene transfer properties250, 312.  
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Concluding remarks 
 
The first generation of AAV gene therapy for neurological diseases is based on 
intracranial injections into target structures and has proven effective in numerous 
mouse and large animal models of neurodegenerative diseases313, 314. The 
efficacy of intraparenchymal infusion of AAV vectors for CNS gene therapy has 
improved through the identification of new AAV capsids with better transduction 
and distribution properties315-317, as well as the use of convection-enhanced 
delivery techniques56 and magnetic resonance imaging (MRI)-guided infusion318. 
Several clinical trials have been conducted or are currently underway to test 
intracranial injection of AAV vectors for different neurodegenerative diseases36, 99, 
100, 118, 128, 319.  
 
There is an increasing recognition that many neurodegenerative diseases affect 
more than a single structure in the CNS and dominant phenotypic manifestations 
driven by a particular structure may be a reflection of different kinetics of disease 
progression across neuronal populations. Therapeutic efficacy in these disorders 
will therefore depend heavily on efficiently targeting all structures involved in 
disease pathophysiology. Huntington’s disease (HD) is an example of an 
evolving perspective on target structures for therapeutic intervention. A recent 
study using transgenic HD mice showed that combined deletion of mutant 
huntingtin (Htt) in cortical and striatal neurons is necessary to ameliorate all 
behavioral deficits and neurodegeneration, while deletion in each population 
individually resulted only in partial effects53. The implication is that transformative 
clinical outcomes in a disease like HD may only be achieved when therapeutic 
interventions are effective across multiple brain structures. The same case could 
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be made for numerous other neurodegenerative diseases with diverse 
neuropathological features. Achieving global gene transfer to the CNS using 
intraparenchymal injections is a daunting, perhaps impossible task, especially 
considering the complex geometry and volume of the cortices. Transport of AAV 
vectors from the injection site to axonally connected structures can expand the 
therapeutic reach of local interventions51, 320-322, but massive doses may be 
needed to achieve significant transduction and coverage in distal structures.  
  
The discovery that AAV9 can cross the blood-brain barrier (BBB) after 
intravascular delivery in neonatal and adult animals was a critical step for AAV-
based CNS gene therapy68. Other AAV capsids such as AAVrh8 and AAVrh10 
were subsequently shown to share this property69, 323. Several studies have 
demonstrated the therapeutic efficacy of intravenously delivered AAV9 vectors in 
animal models of spinal cord motor neuron degeneration79, 107 and 
neurometabolic disorders84, 88, 90. However, while intravascular infusion of AAV9 
is efficient for gene delivery to spinal cord motor neurons68, 69, dorsal root 
ganglia324 and enteric nervous system neurons325, 326, the vast majority of 
transduced cells in the brain are either glia or endothelial cells with sparse 
neuronal transduction68, 70. The tropism of AAV9 to spinal cord motor neurons, 
which is consistent across species68, 76, 324, contributed to the phenotypic rescue 
of spinal muscular atrophy mice treated at post-natal day 2 (PND2) by systemic 
infusion of an AAV9 vector encoding survival motor neuron (SMN) protein79. 
However the effectiveness of AAV9-SMN treatment declined rapidly with age and 
infusion at PND5 showed only a modest survival benefit and no effect by 
PND1079. The reduced therapeutic benefit with age correlated with declining 
transduction of spinal cord motor neurons at older ages when most transduced 
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cells were glia79. While systemic delivery of AAV9 vectors has proven 
exceptionally efficient in mouse models of Canavan disease treated as late as 
PND2084 and in adult models of lysosomal storage diseases88, 90, therapeutic 
efficacy in these diseases is likely less dependent on neuronal transduction. In 
Canavan disease, it is possible that any transduced cell overexpressing 
aspartoacylase may function as a metabolic sink for NAA84. In lysosomal storage 
disorders, there is a cross correction mechanism in which AAV transduced cells 
secrete large quantities of functional enzyme that is taken up and correctly 
targeted to the lysosomes of enzyme deficient cells. Therefore, disperse NAA 
metabolic sinks or sources of functional lysosomal enzymes throughout the CNS, 
regardless of phenotype, are likely to exert a powerful therapeutic effect. Most 
neurological diseases however are unlikely to benefit from such mechanisms and 
will require efficient neuronal gene transfer to change the course of disease 
progression. There is therefore a clear need for AAV capsids with improved 
neuronal transduction properties to develop the next generation of gene 
therapies for multi-focal neurodegenerative diseases. Here we have developed a 
toolbox of AAV capsids with novel or enhanced properties through peptide 
display on capsids of natural and re-engineered AAV isolates (Chapter 3) and 
biopanning of shuffled AAV capsid library (Chapter 4). 
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CHAPTER II 
Materials and Methods 
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Generation of packaging constructs 
 
AAV9.47 trans packaging plasmid was generated by replacing a portion of the 
AAV9 cap sequence in packaging plasmid pAR-9 with a de-novo synthesized 
fragment carrying the following mutations S414N, G453D, K557E and T582I 
described in the original work245 (GenScript USA Inc., Piscataway, NJ) (amino 
acid numbering beginning at VP1) using In-Fusion cloning kit (Clontech 
Laboratories Inc., Mountain View, CA). Packaging plasmid necessary to express 
either only VP1 and VP3 capsid proteins, or VP2 protein fused to peptide were 
generated by introducing point mutations (T138A substitution to generate VP1,3 
plasmids; M1L for VP2 plasmids) as described for AAV2196. Peptide and linker 
(G4S) coding sequences were cloned at the N-terminus of VP2 using In-Fusion 
cloning kit to generate peptide-VP2 expression plasmids. 
 
Library construction 
 
PCR-based DNA shuffling was performed similar to a previously described 
protocol295. Capsid ORFs from AAV1, 2, 4, 5, 6, 8, 9, rh8, rh10, rh39 and 
AAVrh43 were PCR amplified with primers designed to insert unique HindIII and 
XbaI sites at the 5’ and 3’ end of cap gene, respectively, cloned into an universal 
vector (Zero Blunt TOPO, Life Technologies, Grand Island, NY) and digested 
with HindIII and XbaI. Equimolar amounts of the resulting digested cap fragments 
were mixed together and fragmented with DNase I (Roche Diagnostics, 
Mannheim, Germany). Fragments less than 500 bp in length were gel purified 
and assembled by cycling 250 ng of purified DNA using Taq polymerase 
(Platinum Taq DNA Polymerase High Fidelity, Thermo Scientific, Rockford, IL). 
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Cycling conditions were as follows: 94°C, 5 mins; 35 cycles of (94°C, 30 secs; 
slow ramping from 65°C to 41°C over 10 mins; 72°C, 4 mins); 72°C, 7 mins. 
Chimeric cap genes were amplified from assembled DNA (Extensor Long Range 
PCR Enzyme, Thermo Scientific), digested with HindIII and XbaI and subcloned 
into pSub201 packaging plasmid digested with the same restriction enzymes. 
Shuffled plasmid library was generated by transformation of the subcloned library 
into high efficiency bacterial cells (MegaX DH10B T1 electrocompetent cells, 
Thermo Scientific), followed by isolation of plasmid DNA. Maximum theoretical 
diversity of plasmid library was calculated based on colony counts obtained from 
representative aliquot of bacteria transformed with plasmid library.  
 
Packaging of the viral library was done as previously described293. Briefly, 
HEK293T cells grown in 150 mm dishes were transfected with 4 ng shuffled 
plasmid library and 25 µg each of pBluescript and pFΔ6 adenoviral helper 
plasmid using HEPES-buffered saline (HeBS) / calcium chloride co-transfection 
method. 72 h after transfection, cells were harvested and viral library was purified 
by iodixanol gradient ultracentrifugation327, 100 kilodalton molecular weight cutoff 
(MWCO) concentration and dialysis in 1X PBS. DNase resistant vector genome 
titer was determined by quantitative PCR (qPCR). Details of virus purification and 
titration are provided in a subsequent section.  
 
In vivo library selection 
 
1x1011 or 5x1011 vector genomes of viral library were infused into adult 6-8 week 
old male C57BL/6J mice through intravenous route (tail vein) (N=1). 3 d after 
infusion, mice were euthanized, and brain and liver harvested. Total DNA were 
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isolated using DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) and 
tissue-resident capsid genes were amplified by nested PCR using primers 
designed to bind to 5’ and 3’ ends of cap region. Nucleotide and amino acid 
alignment and homology quantification were performed using Geneious 
(Biomatters, Auckland, New Zealand). 
 
Vector particle production, titer quantification and quality analysis  
 
The self-complementary AAV-CBA-GFP vector used in these studies carries an 
expression cassette comprised of the CBA promoter without an intron to drive 
expression of GFP and a rabbit β-globin poly-adenylation signal69.  
Sequences targeting mouse Htt mRNA were embedded into the artificial miR-155 
scaffold to generate the following cassette: 5’-
ctggaggcttgctgaaggctgtatgctgTTTAGACTTGTGTCCTTGACCTgttttggccactgactg
acTGGCAAAGCACAAGTCTAAAcaggacacaaggcctgttactagcactcacatggaacaaatg
gcc-3’ (targeting sequence in bold uppercase). This artificial miRNA targets 
position 1090 in exon 8 of mouse huntingtin gene. eGFP and artificial miRNA 
cassette were expressed under the control of the cytomegalovirus 
enhancer/chicken β-actin promoter (CBA) containing the β-actin exon and 
chimeric intron.  
To generate AAV vectors, HEK293T cells were co-transfected with the following 
mix of plasmids using the calcium phosphate precipitation method: 7.96 µg 
transgene plasmid, 25.6 µg adenoviral helper plasmid pFΔ6, 12.2 µg AAV-B1 or 
AAV9 rep-cap packaging plasmid, per 2.1 x 107 cells plated. To generate 
peptide-grafted AAV vectors, the single rep-cap packaging plasmid was 
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substituted by a 5:1 ratio of VP1,3 packaging plasmid and peptide-VP2 
packaging fused expression plasmid in trans, for a total amount of 12.2 µg, per 
2.1 x 107 cells plated. 72 hours post transfection, cells were harvested and cell 
lysates prepared by 3 cycles of freeze-thaw and treated with Benzonase (Sigma-
Aldrich, St. Louis, MO) (50 U/mL cell lysate, 37°C, 30 min). AAV was purified 
from cell lysates by iodixanol density gradient ultracentrifugation327 (Optiprep 
density gradient medium, Axis-Shield, Oslo, Norway). Residual iodixanol was 
removed by replacing with Buffer B (20 mM TRIS, 0.5 M NaCl, pH 8.5) using a 
100 kilodalton (kDa) cutoff centrifugation device (Amicon Ultra-15, Merck 
Millipore Ltd., Cork, Ireland) by three rounds of centrifugation at 1500x g and 
dialyzed twice using a 10,000 molecular weight cutoff (MWCO) dialysis cassette 
(Slide-A-Lyzer, Thermo Scientific, Rockford, IL) against a 1,000-fold volume 
of PBS for >2h and once overnight at 4°C. After treatment of stocks with DNase I 
(Roche Diagnostics GmbH, Mannheim, Germany, 2 U/µL vector, 37°C, 30 min), 
the titer of AAV vectors was determined by real-time quantitative PCR (qPCR) 
using probe and primers specific for the rabbit β-globin polyA sequence 
(Integrated DNA Technologies, Coralville, IA). For stoichiometric analysis of 
capsid proteins, 1 x 1010 vector particles of purified vector were subjected to 
Western blotting by standard SDS-PAGE technique. AAV capsid proteins were 
detected using mouse monoclonal anti-AAV capsid protein antibody clone B1 
(1:500, American Research Products, Inc., Waltham, MA, 03-65158), peroxidase 
linked anti-mouse secondary antibody (1:2000, GE Healthcare UK Ltd., 
Buckinghamshire, UK, 380199) and ECL Western Blotting Substrate (Pierce 
Protein Research Products, Rockford, IL). 
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Vector administration and tissue processing 
 
The Institutional Animal Care and Use Committees at the University of 
Massachusetts Medical School and Auburn University reviewed and approved all 
experiments in mice and cats, respectively, in compliance with guidelines from 
the National Institutes of Health.  
 
For studies with AAV-AS vector, AAV vectors were administered via the tail vein 
in a volume of 200 µL into 6-8 week-old male C57BL/6J mice (Jackson 
Laboratory, Bar Harbor, ME). A dose of 5 x 1011 vg/mouse was administered for 
immunochemical studies and biodistribution analysis.  
For immunochemical and GFP fluorescence studies, mice were trans-cardially 
perfused at 4 weeks post-injection first with ice cold 1x phosphate buffer saline 
(PBS), followed by 4% paraformaldehyde solution (Fisher Scientific, Fair Lawn, 
NJ). Tissues were harvested and post-fixed in 4% paraformaldehyde solution at 
4°C for an additional 24 h. Post-fixed tissues were transferred to 30% sucrose in 
1x PBS for cryoprotection. Tissues were embedded in Tissue-Tek O.C.T. 
compound (Sakura Finetek, Torrance, CA) and frozen in a dry-ice-isopentane 
bath and stored at -80°C. 
 
For studies with AAV-B1 vector, AAV vectors were administered via the tail vein 
in a volume of 200 µL into 6-8 week-old male C57BL/6J mice (Jackson 
Laboratory, Bar Harbor, ME). A dose of either 5 x 1011 or 2 x 1012 vector 
genomes (vg)/mouse was administered for immunochemical studies, while a 
dose of 5 x 1011 vg/mouse was administered for biodistribution analysis.  
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For immunochemical studies of CNS and GFP fluorescence studies of liver, mice 
injected at a dose of 2 x 1012 vg/mouse were trans-cardially perfused at 4 weeks 
post-injection first with ice cold 1x phosphate buffer saline (PBS), followed by 4% 
paraformaldehyde solution (Fisher Scientific, Fair Lawn, NJ). Tissues were 
harvested and post-fixed in 4% paraformaldehyde solution at 4°C for an 
additional 24 h. Post-fixed tissues were transferred to 30% sucrose in 1x PBS for 
cryoprotection. Tissues were embedded in Tissue-Tek O.C.T. compound (Sakura 
Finetek, Torrance, CA) and frozen in a dry-ice-isopentane bath and stored at -
80°C. For all other immunochemical and GFP fluorescence analysis, mice 
injected at a dose of 5 x 1011 vg/mouse were trans-cardially perfused at 4 weeks 
post-infusion with ice-cold 1x PBS. Retinas were removed prior to perfusion. 
Lungs were inflated in 0.5% low melting point agarose in 10% formalin-PBS 
solution post perfusion. 
 
For biodistribution analysis with either vector, mice were trans-cardially perfused 
at 4 weeks post-infusion with ice-cold 1x PBS. Tissues were harvested 
immediately, frozen on dry ice and stored at -80°C. 
 
Cat studies 
 
AAV-AS vector was packaged by University of Massachusetts Medical School 
Viral Vector Core by transient transfection followed by purification by cesium 
chloride sedimentation175, 328, and administered through the carotid artery into a 2 
month old normal domestic short haired cat at a dose of 1.29x1013 vg. The cat 
was not screened for pre-existing anti-capsid neutralizing antibodies. AAV-B1 
vector was packaged and purified by iodixanol gradient purification as described 
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in an earlier section, and administered through the carotid artery into a 2 month 
old normal domestic short haired cat at a dose of 3.4x1012 vg. 
 
At 4 weeks post infusion, the injected cats was trans-cardially perfused with cold 
1x PBS. Various tissues were harvested and fixed in 4% paraformaldehyde in 
PBS at 4°C. The brain was cut into 0.6 cm coronal blocks prior to immersion in 
fixative. Processing of post-fixed brains and spinal cords for 
immunohistochemical (IHC) and immunofluorescence studies was identical to 
that for mouse studies. 
 
Immunohistochemical detection of GFP expression 
 
For chromogenic IHC, 40 µm serial sections of brains and 30 µm serial sections 
of spinal cord were incubated for 96 h in anti-GFP primary antibody (ABfinity 
rabbit monoclonal anti-GFP 1:1000, G10362, Life Technologies, Grand Island, 
NY), or overnight in anti-GFAP (rabbit polyclonal anti-GFAP 1:500, Z0334, Dako, 
Glostrup, Denmark) or anti-Iba1 (rabbit polyclonal anti-Iba1 1:1000, 019-19741, 
Wako, Osaka, Japan) at 4°C. After washing with 1x PBS, sections were 
incubated in appropriate biotinylated secondary antibody (biotinylated anti-rabbit 
antibody, Vector Laboratories Inc., Burlingame, CA), followed by incubation in 
ABC reagent (PK-6100, Vector Laboratories Inc.). Sections were developed with 
3,3′-diaminobenzidine reagent (DAB) according to the manufacturer’s instructions 
(SK-4100, Vector Laboratories Inc.), dehydrated with increasing concentrations 
of ethanol, cleared with xylene and mounted using Permount mounting medium 
(Fisher Scientific). 
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For immunofluorescence studies, 40 µm sections of brains and 30 µm sections of 
spinal cord were incubated for 24 h in a cocktail of appropriate primary antibodies 
at 4°C. The primary antibodies used were: rabbit polyclonal anti-GFP (1:1000, 
Life Technologies, A11122), chicken polyclonal anti-GFP (1:2000, Abcam, 
ab13970), mouse monoclonal anti-NeuN (1:500, EMD Millipore, MAB377), 
mouse monoclonal anti-DARPP32 (1:250, BD Biosciences, 611520), mouse 
monoclonal anti-tyrosine hydroxylase (1:100, EMD Millipore, MAB318), mouse 
monoclonal anti-calbindin-D-28K (1:500, Sigma, C9848), mouse monoclonal anti-
APC (1:1000, EMD Millipore, OP80), rabbit polyclonal anti-CD31 (1:50, Abcam, 
ab28364) and mouse monoclonal anti-GFAP (1:500, Abcam, ab4648). After 
washing in 1x PBS, sections were incubated for 1 h at room temperature in 
appropriate secondary antibodies, washed in 1x PBS and mounted using 
Permafluor mounting media (Thermo Scientific). Native GFP fluorescence in liver 
and skeletal muscle (quadriceps) was analyzed in 30 µm sections mounted using 
Permafluor mounting media. Native GFP fluorescence in liver and muscle groups 
was analyzed in 30 µm formalin fixed sections, and 10 µm frozen sections, 
respectively. 7 µm formalin fixed pancreatic sections were analyzed with the 
following primary antibodies: rabbit polyclonal anti-GFP (1:1000, Life 
Technologies, A11122), and guinea pig polyclonal anti-insulin (1:200, Abcam, 
ab7842). GFP expression in 10 µm formalin fixed lung sections was detected by 
chromogenic IHC after 24 h incubation with rabbit polyclonal anti-GFP antibody 
(1:1000, Life Technologies, A11122). Retinas were immunochemically processed 
as previously described (Punzo 2009), using rabbit polyclonal anti-GFP (1:1000, 
Life Technologies, A11122). All images were captured on a Leica DM5500 B 
microscope (Leica Microsystems Inc., Buffalo Grove, IL), except the muscle 
groups, which were imaged on a Zeiss microscope with Axiocam system. Post-
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processing of images was performed using Adobe Photoshop CS6 (Adobe 
Systems, San Jose, CA).  
 
Quantification of GFP-positive neurons in striatum and thalamus 
 
Chromogenic IHC staining of 40 µm mouse brain sections was performed as 
described in an earlier section. Five 663.28 µm x 497.40 µm regions were 
randomly chosen from the striatum or thalamus (n=4 biological replicates per 
vector) of the stained sections. Neurons were identified by their morphology and 
counted by individuals blinded to the study design. All statistical analyses were 
performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Total 
neurons in the 663.28 µm x 497.40 µm fields were counted in Nissl (cresyl violet 
acetate) stained brain sections using ImageJ software. Significance was 
determined by Student’s unpaired two-tailed T-test. A p<0.05 was considered to 
be significant. 
 
Biodistribution analysis 
Vector genome copy numbers from various mouse tissues were determined by 
qPCR after extraction of total DNA using DNeasy Blood and Tissue kit (Qiagen). 
Tissues were mechanically lysed using TissueLyzer II (Qiagen GmbH, Hilden, 
Germany). Vector genome content in each tissue was determined using 100 ng 
total DNA using the same qPCR method described above for AAV vector titration 
using a plasmid-based standard curve, and a viral vector internal control for 
quality assurance. All statistical analyses were performed using GraphPad Prism. 
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Significance was determined by Student’s unpaired two-tailed T-test. A p<0.05 
was considered to be significant. 
Western blotting to detect GFP protein levels in various tissue types was 
performed using primary antibodies detecting GFP (chicken polyclonal anti-GFP, 
1:2000, Aves Labs Inc., Tigard, OR, GFP-1010) and mouse β-actin (mouse 
monoclonal anti-β-actin, 1:1000, Sigma-Aldrich, St. Louis, MO, A5441), followed 
by appropriate IRDye secondary antibodies (LI-COR Inc., Lincoln, NE). Total 
protein was isolated from harvested tissues by bead lysis in T-PER tissue 
extraction reagent (Life Technologies) and quantified by Bradford assay. 20 µg of 
total protein was loaded onto each well of 4-20% Mini-PROTEAN TGX gels (Bio-
Rad Laboratories Inc., Hercules, CA). Tissues from two representative mice per 
group were used for analysis. Detection and quantification were done with 
Odyssey infrared imaging system (LI-COR Inc.). 
 
In vitro binding assay 
 
Pro5 and Lec2 CHO cell lines were gifts from Dr. Aravind Asokan (University of 
North Carolina, Chapel Hill, NC) and binding assay was performed as previously 
described205. Briefly, cells were pre-chilled for 30 min at 4°C in serum-free DMEM 
(Life Technologies), followed by incubation with AAV vectors at 4x104 vg/cell in 
cold serum-free media DMEM at 4°C. 90 min later, cells were washed thrice with 
cold serum-free DMEM to remove loosely bound vector particles. Cells were 
harvested and total DNA was extracted using DNeasy Blood and Tissue kit 
(Qiagen). Vector genome copy numbers of cell surface bound virions was 
quantified by qPCR as described earlier. 
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In vitro knockdown assay 
 
A 159 bp sequence containing the Htt mRNA target sequence was cloned into 
pSiCHECK-2 vector (Promega Corporation, Madison, WI) between the XhoI and 
NotI restriction sites in the 3’ UTR of the Renilla luciferase gene. Luciferase 
assays were performed by co-transfection in 24 well plates with 0.025 µg/well of 
the Htt target- containing pSiCHECK-2 reporter and 0.6 µg/well of GIPZ or AAV 
transgene plasmid containing either Htt targeting- artificial miRNA sequence 
(miRHtt) or scrambled miRNA sequence. Transfections were performed using 
Lipofectamine 2000 (Invitrogen Corporation, Carlsbad, CA), according to the 
manufacturer’s protocol. 48 hours after transfection the cells were lysed for 20 
min in 1x passive lysis buffer (Promega). Luciferase activity was read in 96-well 
plates with the Dual-luciferase assay kit (Promega) using the GloMax multi-
detection system (Promega). Renilla luciferase values were normalized for 
intraplasmid transfection efficacy to firefly luciferase signal. All statistical 
analyses were performed using GraphPad Prism. Significance was determined 
by Student’s unpaired two-tailed T-test. A p<0.05 was considered to be 
significant. 
 
Analysis of in vivo Htt knockdown 
 
AAV vectors were administered intravascularly via the tail vein into 6-8 week-old 
male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) at a dose of 9.4x1011 
vg/mouse. Mice were euthanized at 4 weeks post-injection and the brain 
sectioned in 2 mm coronal blocks using a brain matrix. Biopsy punches of 
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different diameters (2 or 3 mm) were used to sample motor cortex (2 mm), 
striatum (3 mm) and thalamus (3 mm). Cervical spinal cord and liver were also 
included in the analysis. Tissue samples were mechanically homogenized using 
a TissueLyzer II and 5 mm stainless steel beads (Qiagen) in Trizol (Life 
Technologies). Total RNA was isolated using Direct-zol RNA MiniPrep kit (Zymo 
Research Corporation, Irvine, CA) according to manufacturer’s protocol. Total 
RNA (400-1000 ng) was reverse transcribed using High Capacity RNA to cDNA 
kit (Applied Biosystems, Foster City, CA). Relative mouse Htt mRNA expression 
was assessed by qPCR using TaqMan gene expression assays  for mouse Htt 
(Mm01213820_m1, Applied Biosystems) and hypoxanthine 
phosphoribosyltransferase 1 (Hprt1; mm00446968_m1, Applied Biosystems). 
Changes in Htt mRNA for groups injected with AAV9 or AAV-AS vectors were 
calculated relative to PBS-injected mice using the 2-∆∆CT method329. Significance 
was determined by Student’s unpaired two-tailed T-test. A p<0.05 was 
considered to be significant. 
For protein analysis, a frozen punch from each region (motor cortex, striatum, 
thalamus, cervical spinal cord, and liver) was homogenized in 75-300 µl 10mM 
HEPES pH7.4, 250mM sucrose, 1mM EDTA + protease inhibitor tablet 
(cOmplete mini, EDTA-free, Roche), 1mM NaF and 1mM Na3VO4 on ice for 30 
strokes.  Protein concentration was determined by Bradford method (BioRad) 
and 10µg motor cortex, striatum, and thalamus or 20µg cervical spinal cord and 
liver were loaded onto 3-8% Tris-Acetate gels (Life Technologies) and separated 
by SDS-PAGE.  Proteins were transferred to nitrocellulose using a TransBlot 
Turbo apparatus (BioRad) then blots were cut horizontally at 72kD.  Blots were 
washed in TRIS-buffered saline + 0.1% Tween 20 (TBST) and blocked in 5% 
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milk/TBST.  The top half of the blot was incubated in anti-Htt antibody Ab1330 
(1:2000) and the bottom half in anti-tubulin antibody (1:4000, Sigma) or anti-
GAPDH antibody (1:6000, Millipore) diluted in 5% milk/TBST overnight at 4°C.  
Blots were washed in TBST then incubated in peroxidase conjugated secondary 
antibodies diluted in 5% milk/TBST for 1 hour at room temperature, washed, and 
proteins were detected using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific) and FluoroChem SP (Alpha Innotech) and 
Hyperfilm ECL.  The bottom blots were reprobed with anti-GFP antibody (1:3000, 
Cell Signaling).  Densitometry was performed using ImageJ software. 
 
Structural analysis 
 
Alignment of AAV-B1 capsid protein sequence with parental serotypes was 
carried out using Cobalt Constraint-based Multiple Protein Alignment Tool. The 
capsid sequence ordering was arranged using Chimera 
(http://www.cgl.ucsf.edu/chimera) in descending percent identities referenced to 
AAV8. The 3D model of AAV-B1 was generated using SWISS MODEL 
subroutine331 based on coordinates from the AAV8 crystal structure186 (PDB 
accession no. 2QA0) as a template. Surface mapping was performed using 
Pymol (http://www.pymol.org). 
 
Antibody neutralization assay 
 
Anti-AAV neutralization assay was performed as previously described332. Briefly, 
AAV vectors were mixed with varying concentrations of Gammagard S/D purified 
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intravenous immunoglobulin (IVIg), (Baxter, Deerfield, IL, gift from Dr. Luk H. 
Vandenberghe, Harvard Medical School, MA) in serum-free media, incubated for 
1 h at 37°C and then added to HeLa cells at 3.5x104 v.g./cell at 37°C. AAV 
incubated with PBS (no IVIg) served as control. 90 min later, cells were washed 
thrice with cold serum-free media and replacing with complete media, cells were 
incubated for 48 h prior to trypsinization and preparation for flow cytometry. Cell 
samples were analyzed for GFP expression using the blue laser of a BD LSR 
Fortessa™ flow cytometer (San Jose, CA) running BD FACSDiva™ software 
(v6.1.3). Flow data was analyzed using FLOWJo software (FLOWJo, LLC, 
Ashland, OR). To calculate % transduction of control for the samples mixed with 
IVIg, % GFP positive cell values for each sample were plotted as a percentage of 
the AAV transduction sample without IVIg, which was set to 100%. 
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CHAPTER III 
Widespread CNS gene transfer and silencing after systemic delivery of 
novel AAV-AS vector 
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Abstract 
 
Effective gene delivery to the central nervous system (CNS) is vital for 
development of novel gene therapies for neurological diseases. Adeno-
associated virus (AAV) vectors have emerged as an effective platform for in vivo 
gene transfer, but overall neuronal transduction efficiency of vectors derived from 
naturally occurring AAV capsids after systemic administration is relatively low. 
Here we investigated the possibility of improving CNS transduction of existing 
AAV capsids by genetically fusing peptides to the N-terminus of VP2 capsid 
protein. A novel vector AAV-AS, generated by the insertion of a poly-alanine 
peptide, is capable of extensive gene transfer throughout the CNS after systemic 
administration in adult mice. AAV-AS is 6- and15-fold more efficient than AAV9 in 
spinal cord and cerebrum, respectively. The neuronal transduction profile varies 
across brain regions but is particularly high in the striatum where AAV-AS 
transduces 36% of striatal neurons. Widespread neuronal gene transfer was also 
documented in cat brain and spinal cord. A single intravenous injection of an 
AAV-AS vector encoding an artificial microRNA targeting huntingtin (Htt) resulted 
in 33-50% knockdown of Htt across multiple CNS structures in adult mice. This 
novel AAV-AS vector is a promising platform to develop new gene therapies for 
neurodegenerative disorders. 
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Results 
 
Insertion of poly-alanine peptide in AAV9.47 capsid enhances neuronal 
gene transfer in adult mice 
We chose AAV9.47 as the capsid in which to test our peptide grafting approach 
as this quadruple mutant of AAV9 (S414N, G453D, K557E, T582I) has 
comparable CNS gene transfer properties to AAV9 but decreased tropism to 
liver245 (Figure 3.1). Peptides were grafted on the AAV9.47 capsid surface via 
genetic fusion to the N-terminus of VP2 using a previously described approach196 
(Figure 3.2a). Unexpectedly, one of the control vectors used for this screen, a 
peptide-modified AAV9.47 vector carrying a string of 19 alanines in the VP2 
capsid protein, designated as AAV-AS (Figure 3.2b), showed a remarkable 
increase in CNS transduction efficiency compared to AAV9 after systemic 
delivery in 6-8 week old C57BL/6 mice (Figure 3.3a). AAV-AS vector transduced 
diverse neuronal populations, glia and endothelia throughout the brain and spinal 
cord, including extensive transduction of neurons in motor cortex and striatum 
(Figure 3.3b). We also observed efficient transduction of granule cells in the 
dentate gyrus as well as motor neurons and interneurons in the spinal cord 
(Figure 3.3b). The identity of GFP-positive cells with neuronal morphology in 
cortex, striatum and spinal cord was confirmed by co-localization of GFP and 
NeuN (Figure 3.3c). GFP-positive neurons in the striatum were shown to be 
DARPP32-positive medium spiny neurons (Figure 3.3c). Neuronal transduction 
was apparent in many brain regions of AAV-AS injected mice with the exception 
of thalamus and hypothalamus where only sparse transduction was observed 
(Figure 3.4). AAV-AS also transduced GFAP-positive astrocytes (Figure 3.3c), 
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oligodendrocytes in the corpus callosum and Bergmann glia in the cerebellum 
(Figure 3.4). The transduction profile of AAV9 was limited to glial cells and 
endothelia in most CNS regions analyzed (Figure 3.3b and Figure 3.4). 
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Figure 3.1: Biodistribution profile of AAV9.47. (a) AAV vector genome content 
in cerebrum, spinal cord, liver and muscle of mice injected intravenously with 
AAV9.47-GFP or AAV9-GFP vectors (5x1011 vg/mouse) (n=4 animals per group). 
(b) Quantification of GFP-positive neurons per high power field in striatum and 
thalamus of injected mice (n=4 biological replicates per group). Data shown as 
mean ± SD. **p < 0.01 by Student’s unpaired two-tailed t-test.
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Figure 3.2: Construction of AAV-AS vector. (a) Illustration of packaging 
strategy. VP1 and VP3 are expressed separately (top) from VP2 fused with 
peptide (below). (b) Schematic diagram of VP2 capsid protein showing insertion 
site of AS peptide and G4S linker. 
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Figure 3.3: CNS transduction profile of AAV-AS vector after vascular 
infusion in adult mice.  
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Figure 3.3: CNS transduction profile of AAV-AS vector after vascular 
infusion in adult mice. a. Overview of GFP distribution in brain and spinal cord 
in AAV-AS and AAV9 injected mice (5x1011 vg/mouse). Representative images of 
coronal brain sections located in relation to bregma at +0.5mm, -0.5mm and -
1.80mm, and cervical spinal cord (left to right) are shown. b. Transduction of 
neuronal populations in different brain regions. Black arrows indicate examples of 
GFP-positive neurons identified by morphology. Bar = 50 µm. c. Phenotype of 
transduced cells was identified by double immunofluorescence staining with 
antibodies to GFP, pan-neuronal marker NeuN, striatal medium spiny neuron 
marker DARPP32 or astrocyte marker GFAP. Neuronal transduction in spinal 
cord was examined in sections stained for GFP and NeuN. The large size and 
morphology of GFP-positive neurons in the ventral spinal cord suggest a motor 
neuron identity. White arrows indicate examples of GFP-positive neurons. Bar = 
10 µm.  
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Figure 3.4: Transduction profile of AAV-AS and AAV9 vectors across 
multiple CNS regions after systemic delivery.  Bar = 50 µm. Black arrows in 
corpus callosum indicate GFP-positive oligodendrocytes, and in the cerebellum 
indicate Bergmann glia. 
 
 
  
  
70 
Western blot analysis of AAV preparations confirmed incorporation of the 
chimeric poly-alanine VP2 protein in the AAV-AS capsid (Figure 3.5a). 
Quantification of GFP-positive neurons revealed AAV-AS transduced as many as 
36% of striatal neurons compared to only 0.45% by AAV9 (Figure 3.5b). In 
contrast, the increase in transduced thalamic neurons was more modest (Figure 
3.5b). The CNS transduction efficiency of AAV-AS vector was also reflected in its 
biodistribution profile. More vector genomes were found in the cerebrum and 
spinal cord of AAV-AS injected animals compared to AAV9 (15-fold and 6-fold, 
respectively) (Figure 3.5c). These findings were corroborated by comparable 
increase in GFP protein in cerebrum and spinal cord (Figure 3.5d). The 
increased gene transfer efficiency for AAV-AS vector compared to AAV9 appears 
to be restricted to CNS, as transduction of liver, muscle, lung, pancreas and 
kidney was identical for both AAV vectors based on analysis of vector genome 
content (Figure 3.5e and Figure 3.6) and GFP protein levels (Figure 3.5f). No 
inflammatory response characterized by reactive astrogliosis or microgliosis was 
observed due to AAV-AS infusion (Figure 3.7). 
 
As a first step to understand how the poly-alanine peptide enhances CNS 
transduction of AAV9.47, we carried out a cell culture study to determine whether 
it changes the capsid interaction with exposed galactose residues on cell surface 
glycans. Terminal N-linked galactose is the primary cell surface receptor for 
AAV950, 205. Binding studies in parental (Pro5) and sialic acid-deficient (Lec2) 
CHO cells showed no difference in receptor preference between AAV-AS, 
AAV9.47 and AAV9 vectors (Figure 3.8).  
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Figure 3.6: Biodistribution profile of AAV9.47, AAV9 and AAV-AS vectors in 
lung, pancreas and kidney.  AAV vector genome content in mice injected 
intravenously with 5x1011 vg (n=4 animals per group). Data shown as mean ± SD. 
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Figure 3.7: Assessment of gliosis markers in brain upon AAV infusion. Bar 
= 50 µm.  
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Figure 3.8: Cell binding studies of native and peptide-modified AAV vector. 
Data shown as mean ± SD. Experiment was performed with N=3 biological 
replicates. 
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Interestingly, while insertion of the 19-mer poly-alanine into AAVrh8 also led to 
an increase in CNS transduction efficiency (Figure 3.9a), it did not appear to 
enhance neuronal transduction, but instead noticeably increased glial and 
endothelial transduction (Figure 3.9b). Similar to AAV-AS, AAVrh8-AS exhibited 
significantly increased transduction of cerebrum, cerebellum and spinal cord 
(Figure 3.9c), while liver transduction remained unchanged (Figure 3.9d).   
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Figure 3.9: Biodistribution of AAVrh8-AS vector. (a, b) Distribution of GFP-
positive cells in immunostained histological brain sections. Sections represented 
in (a) correspond to coronal planes +0.5mm and -1.80mm from the bregma plane. 
Bar = 50 µm. (c, d) Quantification of AAV vector genome content in (c) different 
CNS regions or (d) liver. Data shown as mean ± SD. Experiment was performed 
with N=3 per group. *p < 0.05, **p < 0.01, ****p < 0.0001 by Student’s unpaired 
two-tailed t-test. 
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AAV-AS transduces neurons throughout the cat brain after systemic 
administration 
Next we assessed whether the neuronal transduction properties of AAV-AS are 
reproducible in cats as there are numerous models of neurodegenerative 
diseases in this species. Consistent with results in mice, AAV-AS transduced 
diverse neuronal populations across the cat brain and spinal cord, including 
neurons in cerebral cortex, striatum and reticular formation, Purkinje neurons in 
cerebellum and motor neurons in the oculomotor nucleus located in ventral 
midbrain, spinal nucleus of the trigeminal nerve in brainstem and throughout the 
spinal cord (Figure 3.10a, b). Curiously, no endothelial and only sparse glial 
transduction was apparent in the cat brain in this study.  
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Figure 3.10: Neuronal transduction in cat after systemic delivery of AAV-AS 
vectors. a. Transduction of neurons in the cat brain after systemic delivery of 
AAV-AS vector (1.29x1013 vg). Representative images (left) show GFP-positive 
cells with neuronal morphology in various structures in the brain and spinal cord. 
Bar = 50 µm. b. Double immunofluorescence staining for GFP and NeuN (right) 
confirm the neuronal identity of GFP-positive cells in brain and spinal cord. White 
arrows indicate examples of GFP-positive neurons. Bar = 50 µm. 
 
  
  
79 
Widespread knockdown of Htt in CNS after systemic delivery of AAV-AS 
vector 
Finally, we evaluated the therapeutic potential of AAV-AS vector for Huntington’s 
disease, a fatal autosomal dominant neurodegenerative disease caused by 
expansion of a CAG repeat in the huntingtin gene333. Currently there is no 
treatment for this devastating disease, but experimental RNAi110, 111 and 
oligonucleotide334 therapies have shown promising results. AAV-AS and AAV9 
vectors encoding GFP and an U6-driven artificial microRNA specific for mouse 
Htt (miRHtt) were infused systemically in C57BL/6 mice. The knockdown 
efficiency of this AAV-miRHtt construct was 93% in a transient transfection assay 
in cell culture (Figure 3.11). Huntingtin mRNA and protein levels in CNS and liver 
were assessed at 4 weeks post injection (Figure 3.12). AAV-AS vector resulted 
in 33-50% reduction in Htt mRNA in striatum, motor cortex and spinal cord, and 
was better than AAV9 in all brain regions, but comparable in the spinal cord 
(Figure 3.12a). Conversely, AAV-AS was less potent than AAV9 in lowering Htt 
mRNA in liver (Figure 3.12a). Western blot analysis of Htt protein levels 
corroborated the differences between AAV9 and AAV-AS in the striatum, motor 
cortex and thalamus as well as in liver (Figure 3.12b). As anticipated, the 
reduction in Htt protein levels was inversely proportional to GFP protein levels, 
which indicates that higher CNS transduction efficiency leads to greater reduction 
in huntingtin mRNA and protein.  
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Figure 3.11: In vitro assessment of knockdown efficiency of miRHtt 
construct. Changes in levels of luciferase reporter for Htt in HeLa cells 
transfected with (a) GIPZ expression plasmid, and (b) AAV transgene plasmid 
(used for in vivo Htt knockdown studies), containing either Htt targeting- artificial 
miRNA sequence (miRHtt) or scrambled miRNA sequence. Values were 
normalized to luciferase levels in scrambled miRNA controls. % knockdown was 
calculated in comparison to scrambled controls. ****p < 0.0001 by Student’s 
unpaired two-tailed t-test. Data shown is mean ± SD. 
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Figure 3.12: Htt knockdown in mice upon intravenous administration of 
AAV-AS-miRHtt vector.  
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Figure 3.12: Htt knockdown in mice upon intravenous administration of 
AAV-AS-miRHtt vector. a. Changes in Htt mRNA levels in brain structures, 
cervical spinal cord and liver in wild type mice injected systemically with AAV-AS 
or AAV9 vectors (n=4 per group) (9.4x1011 vg/mouse) encoding a U6 promoter-
driven artificial microRNA (miRHtt) targeting mouse huntingtin mRNA. Values for 
each region were normalized to Htt mRNA levels in age-matched PBS-injected 
mice. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Student’s unpaired 
two-tailed t-test. Data shown is mean ± error. b. Western blot analysis of Htt and 
GFP protein levels in brain structures, cervical spinal cord and liver of the same 
AAV-injected mice and PBS-injected controls. Values for each region were 
normalized to HTT protein levels in age-matched PBS-injected mice.  *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001  by Student’s unpaired two-tailed t-test. 
Data shown is mean ± SD. 
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CHAPTER IV 
In vivo selection yields novel AAV-B1 capsid for CNS and muscle gene 
therapy 
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Abstract 
 
Adeno-associated viral (AAV) vectors have shown promise as a platform for 
gene therapy of neurological disorders. Achieving global gene delivery to the 
central nervous system (CNS) is key for development of effective therapies for 
many of these diseases. Here we report the isolation of a novel CNS tropic AAV 
capsid, AAV-B1, after a single round of in vivo selection from an AAV capsid 
library. Systemic injection of AAV-B1 vector in adult mice and cat resulted in 
widespread gene transfer throughout the CNS with transduction of multiple 
neuronal sub-populations. In addition, AAV-B1 transduces muscle, beta cells, 
pulmonary alveoli and retinal vasculature at high efficiency. This vector is more 
efficient than AAV9 for gene delivery to mouse brain, spinal cord, muscle, 
pancreas and lung. Together with reduced sensitivity to neutralization by 
antibodies in pooled human sera, the broad transduction profile of AAV-B1 
represents an important improvement over AAV9 for CNS gene therapy. 
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Results 
 
Single round of selection in mouse yields novel synthetic capsids 
We sought to isolate chimeric AAV variants capable of CNS transduction upon 
systemic delivery in adult mice after one round of library selection (Figure 4.1a). 
We constructed an AAV capsid library by DNA shuffling of AAV1, 2, 4, 5, 6, 8, 9, 
rh8, rh10, rh39 and AAVrh43 capsid genes. The parental capsids were chosen 
for their ability to transduce CNS upon intravenous delivery in neonatal mice69. 
The plasmid library had a maximum diversity of 2x107 capsids, based on 
transformation efficiency. Sanger sequencing of individual capsids from the viral 
library confirmed the chimeric nature of capsid genes in the library (Figure 4.2). 
The AAV library was infused into adult C57BL/6 mice via the tail vein at 1x1011 or 
5x1011 genome copies, and tissue resident capsid genes were PCR amplified 
from brain and liver after 3 days. Of capsids isolated from brain, AAV-B1 was the 
only one amplified from the mouse infused at the lower dose, while AAV-B2, B3 
and B4 were isolated from the high dose. In contrast, numerous capsids were 
found in liver of mice infused at either dose, the major depot organ of 
systemically infused AAV. All new AAV capsid genes were chimeric, but the VP3 
capsid genes of brain clones (AAV-B1 through B4) were mostly comprised of 
DNA derived from either AAV8 or AAVrh43 (Figure 4.1b), while liver-isolated 
capsid genes were more diverse (Figure 4.1c). Analysis of capsid protein 
sequences revealed greater homology between capsids isolated from brain 
(97.3% pairwise homology) (Figure 4.1d) compared to capsids isolated from liver 
(88.6% pairwise homology) (Figure 4.1e).  
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Figure 4.1: Single round in vivo biopanning. (a) Selection strategy. (b, c). 
Parental capsid gene contribution to new chimeric capsid genes isolated from (b) 
brain (AAV-B1, -B2, -B3, and -B4) and (c) liver. (d, e) Amino acid homology 
among capsids isolated from (d) brain and (e) liver. Grey areas indicate 
homology; black lines indicate non-homologous amino acids. % homology is 
calculated for amino acid composition. 
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Figure 4.2: Chimeric nature of packaged viral library. a. Parental capsid 
contribution to five capsid genes PCR amplified from packaged viral library. b. 
Homology between capsids at the amino acid level. Grey areas indicate 
homology; black lines indicate non-homologous amino acids. % homology is 
calculated for amino acid composition. 
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Brain-selected AAV-B1 transduces mouse neuronal populations, and is 
superior to AAV9 for CNS gene transfer 
The CNS transduction profile of AAV-B1 was assessed after systemic delivery in 
adult mice using a green fluorescent protein (GFP) expression cassette (Figure 
4.3a). AAV-B1 vector transduced neuronal, glial and endothelial populations 
throughout the CNS (Figure 4.3b, Figure 4.4, Figure 4.5). Neuronal 
transduction was apparent in multiple regions of the cerebral cortex, including the 
primary (Figure 4.3b) and secondary (Figure 4.4) motor and somatosensory 
cortices, cingulate cortex and piriform (olfactory) cortex (Figure 4.3b). A sparse 
number of DARPP32-positive medium spiny neurons in the striatum were found 
transduced (Figure 4.5a). In the hippocampal formation, we found transduced 
granule cells in dentate gyrus (Figure 4.3b, Figure 4.5b) and pyramidal neurons 
in CA1-CA3 areas (Figure 4.4). Similar patterns of gene transfer to hippocampal 
neurons have been reported for AAV973. Neurons in the thalamus (Figure 4.3b, 
Figure 4.5b), hypothalamus, amygdala (Figure 4.3b) and tyrosine hydroxylase 
(TH)-positive dopaminergic neurons in the substantia nigra (Figure 4.5b) were 
similarly transduced with AAV-B1. In the cerebellum, AAV-B1 vector transduced 
Purkinje cells (identified by calbindin D-28K co-staining) (Figure 4.3b, Figure 
4.5c) as well as neurons in the granular layer. Finally, AAV-B1 vector transduced 
motor neurons throughout the spinal cord (Figure 4.3b, Figure 4.4, Figure 4.5d).  
 
In addition to the neuronal tropism, AAV-B1 also transduced endothelial cells in 
the brain and spinal cord identified by the distinct morphology of blood vessels in 
CNS and confirmed by co-staining for CD31 (Figure 4.5e). AAV-B1 also 
transduced glial cells such as mature oligodendrocytes (identified by co-staining 
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for APC) (Figure 4.5f) and astrocytes (identified by morphology) (Figure 4.5g). 
Strong transduction of the choroid plexus was also apparent (Figure 4.4).   
 
Quantitative analysis of AAV vector genomes in different regions of the CNS 
revealed 5.8- to 14.5-fold higher content for AAV-B1 compared to AAV9 (Figure 
4.3c). 
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Figure 4.3: CNS transduction profile of AAV-B1 vector after intravascular 
infusion in adult mice.   
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Figure 4.3: CNS transduction profile of AAV-B1 vector after intravascular 
infusion in adult mice. (a) Overview of GFP distribution in brains of AAV-B1 
and AAV9 injected mice (2x1012 vg/mouse). Representative images of coronal 
brain sections located at +0.5mm, -1.80mm and -3.00mm (left to right) in relation 
to bregma are shown. (b) Transduction of neuronal populations in different CNS 
regions of AAV-B1 injected mice. Black arrows indicate examples of GFP-
positive neurons identified by morphology. Bar = 50 µm. (c) Comparison of AAV 
vector genome content in cerebrum, cerebellum and spinal cord of mice injected 
with 5x1011 vg AAV-B1 or AAV9 (N=4 animals per group). Age matched non-
injected mice were included as controls (not shown). **p < 0.01, ***p < 0.001, 
****p < 0.0001 by Student’s two-tailed unpaired t-test. 
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Figure 4.4: Transduction profile of AAV-B1 vector across multiple CNS 
regions after systemic delivery. Black arrows indicate examples of GFP-
positive neurons. Bar = 50 µm. 
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Figure 4.5: Phenotype of GFP positive cells in CNS after systemic delivery 
of AAV-B1. Transduced cells were identified by double immunofluorescence 
staining with antibodies to GFP, pan-neuronal marker NeuN (a, b and d), striatal 
medium spiny neuron marker DARPP32 (a), dopaminergic neuron marker 
tyrosine hydroxylase (TH) (b), Purkinje neuron marker calbindin-D-28k (Cal28K) 
(c), endothelial marker CD31 (e), and mature oligodendrocyte marker APC (f). 
The large size, morphology and location of GFP-positive neurons in the ventral 
spinal cord suggest a motor neuron identity. GFP-positive astrocytes (g) were 
identified based on their morphology. White arrows indicate examples of co-
localization. Bar = 10 µm. 
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CNS tropism of mouse-selected AAV-B1 extends to a large animal species  
Several novel therapies have been tested in feline models of neurological 
disorders prior to clinical trials314, 335-337. To investigate whether the CNS tropism 
of mouse-selected AAV-B1 is reproducible in a large animal species relevant to 
translational research, we infused AAV-B1 vector systemically into a normal 
juvenile cat through the carotid artery. We observed widespread neuronal gene 
transfer throughout the cat brain (Figure 4.6). Mirroring the neuronal transduction 
pattern in mouse, AAV-B1 transduced neurons in the cat cerebral cortex, 
striatum, hippocampus, thalamus and Purkinje neurons in the cerebellum (Figure 
4.6). In addition, we observed transduced motor neurons throughout the midbrain. 
Unlike in mouse, we found no indication that AAV-B1 transduced endothelial 
cells in the cat CNS.  
  
  
95 
 
 
Figure 4.6: Neuronal transduction in cat brain after systemic delivery of 
AAV-B1 vectors. GFP distribution in the cat brain after systemic delivery of 
3.4x1012 vg AAV-B1 vector. Representative images show GFP-positive cells with 
neuronal morphology in various structures in the brain. Image of tract of 
trigeminal nerve shows GFP staining of nerve fibers. Bar = 50 µm.  
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AAV-B1 as a global gene therapy vector 
Next we assessed the peripheral transduction profile of AAV-B1. Liver 
transduction by AAV-B1 was lower than AAV9 as assessed by histological 
examination of GFP expression (Figure 4.7a). The vector genome content of 
AAV-B1 liver was 3-fold lower than AAV9 (Figure 4.7b). AAV-B1 proved to be 
highly efficient in transducing skeletal muscle and heart (Figure 4.7c) where 
vector genome content was 10.4- to 26.6-fold and 14.4-fold higher than AAV9, 
respectively (Figure 4.7d). AAV-B1 also transduced insulin-positive beta cells 
(Figure 4.7e) and lung alveoli (Figure 4.7f) at high efficiency. The vector 
genome content in pancreas and lung was 21.3- fold and 14.1-fold higher for 
AAV-B1 than AAV9, respectively (Figure 4.7g, h). Finally retinal endothelium 
was also transduced at high efficiency (Figure 4.7i), a property that is unique to 
AAV-B1338.  
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Figure 4.7: AAV-B1 biodistribution to other mouse tissues after 
intravascular delivery. GFP expression in (a) liver of AAV-B1 and AAV9 
injected mice (2x1012 vg/mouse), (c) skeletal muscle (triceps and quadriceps), 
diaphragm and heart, (e) pancreas, (f) lung, and (i) retina of AAV-B1 injected 
mice (5x1011 vg/mouse). White arrow in e. indicates GFP (green)-positive insulin 
(red)-producing beta cells. Inset in i. shows individual GFP-positive blood vessels. 
Comparison of AAV vector genome content in (b) liver, (d) muscle groups, (g) 
pancreas and (h) lung of mice injected with 5x1011 vg AAV-B1 or AAV9 is shown 
(N=4 animals per group). *p<0.05, **p < 0.01, ****p < 0.0001 by Student’s two-
tailed unpaired t-test.  
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Biophysical characteristics of AAV-B1 
AAV-B1 differs from AAV8, its closest parental capsid, by 19 amino acids (A24D, 
Q84K, A98V, L129F, P148Q, R152E, T157S, S223N, L235M, A268S, Q412E, 
T414S, T416Q, T452S, N458R, T461Q, G463L, G467A and F502S) (Figure 
4.8). Structural modeling of AAV-B1 capsid based on the AAV8 template showed 
that most amino acids in VP3 that differ between the two capsids cluster in two 
regions, the βG strand (Q412E, T414S, T416Q) and the VR-IV loop (T452S, 
T461Q, G463L, and G467A) that were apparently derived from the AAVrh10 cap 
gene. The A268S substitution in the VR-I loop is a small side chain residue in 
representative AAV serotypes and is considered a conservative change. All 
surface exposed residues in VR-IV were of AAVrh10 origin except for N458R, 
which is not identified with any representative AAV genotypes (Figure 4.9a, b). 
Despite the high degree of homology between AAV-B1 and AAV8, we confirmed 
that AAV-B1 and AAV8 have distinct biodistribution profiles after systemic 
infusion in adult mice (Figure 4.10).  
 
Pre-existing humoral immunity is a major challenge for AAV-based clinical gene 
therapy306. We used a pooled human immunoglobulin-G (IVIG) neutralization 
assay to assess the immunological properties of AAV-B1 and found it to be more 
resistant to neutralization than AAV9 at all concentrations tested (Figure 4.9c).  
 
To determine whether AAV-B1 uses the same cell-surface receptor as AAV9 
given the shared CNS and muscle tropism, we performed cell binding assays 
using parental (Pro5) and sialic acid-deficient (Lec2) CHO cells. Surface exposed 
sialic acid residues allow for binding of capsids such as AAV1200, AAV448, AAV548 
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and AAV6200 to Pro5 cells, while surface glycans on Lec2 cells are non-sialylated 
and thus have exposed galactose residues used by AAV9 as a receptor 50, 205. 
AAV-B1 did not exhibit preferential binding to either cell line, indicating that 
neither terminal sialic acid nor terminal galactose preferentially act as primary 
glycan receptors for AAV-B1 capsid (Figure 4.9d).  
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Figure 4.10: Biodistribution profile of AAV-B1 and AAV8 vectors infused 
systemically at 5x1011 vg. AAV vector genome content (N=4 animals per group) 
in a. CNS, b. liver and c. skeletal muscle (quadriceps) is shown. *p<0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001 by Student’s unpaired two-tailed t-test. 
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CHAPTER V 
Discussion 
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Viral vector-mediated gene therapy holds great promise for treatment of 
neurological disorders. The current benchside efforts continue to be targeted 
towards generating better vectors, both at the virion level (e.g., developing 
capsids capable of crossing the BBB and targeting specific cell types) and at the 
transgene level (e.g., promoter and transgene design to improve efficacy in 
desired cell populations). Better non-invasive vector delivery routes for global 
and widespread CNS gene delivery are also being investigated for multi-focal 
neurological disorders. The result of this has been a slew of clinical trials for CNS 
disorders, which have been shown to be safe and non-toxic in Phase I, but few 
have been as efficacious in demonstrating therapeutic outcomes as perhaps may 
have been expected based on preclinical studies. These early trials have shed 
light on a myriad of challenges that must be surmounted for unequivocal clinical 
success. One of the major problems is the lack of good predictive animal models 
and inherent differences between species, which could be a primary cause of the 
failure of favorable preclinical outcomes to translate to the clinic. The potential of 
immune responses, both against the vector and expressed transgene, is often 
overlooked for neurological gene therapy, as the CNS is considered immune-
privileged. This assumption has had to be revised in recent years as studies 
have demonstrated not only the generation of anti-capsid neutralizing antibodies, 
but also immune-mediated clearance of transduced antigen-presenting cells in 
the CNS339, 340, which raises concerns for the next generation of CNS gene 
therapy clinical trials. More insight into the etiology of neurological disorders and 
particularly the development of biomarkers for early detection of disease will be 
of great help moving forward, as delivering therapies prior to onset of 
neurodegeneration will be key to improving efficacy of clinical intervention. Finally, 
recent advances in gene editing technologies, particularly CRISPR-Cas9, could 
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lead to a move away from the current gene replacement therapies towards more 
permanent genome editing. The regulatory approval of Glybera, an AAV1 clinical 
vector for lipoprotein lipase deficiency, in the European Union, the US FDA 
regulatory approval for the oncolytic HSV-based T-VEC for therapy of advanced 
melanoma, and the recent encouraging results of Phase III clinical trials of AAV2-
based SPK-RPE65 vector for inherited retinal dystrophies (IRDs) has raised 
hopes that similar success may follow for gene therapy of neurological disorders 
in the future. 
 
As outlined in Chapter I, the utility of AAV vectors for gene transfer is determined 
by the capsid, which is involved in several key cell entry steps. In-depth 
understanding of the capsid structure-function relationship, either through 
elucidation of AAV structure or through functional studies, has resulted in 
development of improved variants that possess a number of features such as 
enhanced transduction of a particular cell population in vitro or in vivo, altered 
tropism, or increased evasion of neutralizing antibodies, among others. Several 
challenges exist, however, before a greatly expanded toolbox of such vectors 
can be created for clinical use. Chief among them is the translatability of 
properties of capsids selected in cell culture or even in mice or NHPs, to humans. 
Even reproducibility of transduction profiles from in vitro to in vivo application is 
difficult, due to additional complicating factors such as blood-organ barriers that 
prevent the virus from interacting with target cells in vivo. The lack of exhaustive 
knowledge of all capsid interactions with the host cell, or even the host cell 
glycan receptors for every serotype, further compounds the challenge. The 
mechanism by which re-engineered capsids (particularly those isolated by library 
approaches) derive their superior gene transfer properties is almost entirely 
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unknown, which means that most capsid re-engineering efforts are semi-
mechanistic at best. A consequence of the non- or semi-mechanistic approach to 
capsid engineering is that the designed capsid may exhibit properties different 
from the desired one. For example, AAVM41, originally selected from skeletal 
muscle, targets cardiac muscle preferentially247. Finally, variability in observed 
biological properties of a capsid between reports is concerning. Numerous 
examples abound, such as whether the human hepatocyte-selected AAVLK03 is 
superior to AAV8 or the very similar AAV3B at targeting hepatocytes of human 
origin249, 341, or whether surface tyrosine-mutated AAV8 and AAV9 vectors 
enhance gene transfer286, to mention a couple. Many factors could be 
responsible, such as injected dose and volume342, 343, or even method of vector 
production344, all of which can influence the tropism of a particular capsid. Even 
the use of ubiquitous promoters, which conventionally can drive expression in 
numerous cell types, can skew the apparent transduction profile of a capsid. For 
example, intraparenchymal injections with ubiquitous CBA-315, 345, CMV-346, 347 or 
RSV-31 encoded AAV vectors indicate an almost exclusive neurotropic profile for 
most AAV serotypes with negligible gene transfer to other cell populations in the 
CNS; however, the same serotypes can mediate robust transduction of other cell 
types such as astrocytes348 and oligodendrocytes348, 349 when expression is 
driven by cell-specific promoters. One field that is likely to benefit in particular 
from further insight into capsid biology, is gene therapy for neurological disorders, 
where capsid re-engineering can lead to improved vectors allowing widespread 
genetic access across the brain and spinal cord. 
 
The enhanced CNS transduction properties of AAV-AS represent an important 
improvement from AAV9 toward the ultimate goal of achieving gene transfer to 
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the majority of cells in the CNS, particularly neurons. The neuronal transduction 
efficiency of recently discovered capsids capable of crossing the adult BBB (such 
as AAVrh8 and AAVrh10) is not quantitatively higher than AAV970. In contrast, 
the new AAV-AS vector described here is more efficient than AAV9 at 
transducing neurons in striatum and cerebral cortex. In addition, transduced 
motor neurons are evident in the spinal cord of AAV-AS injected mice, in contrast 
to AAV9 used in these experiments and in prior work68. Nonetheless the CNS 
transduction profile of AAV9 in this study appears less robust than in previous 
publications73, 323, possibly due to the lower dose and the relatively weak intron-
less promoter used in this study. While we are unable to completely exclude the 
possibility that the potency of our AAV9 vector is lower than those from other 
laboratories, we believe this is unlikely a major factor in the results reported here 
because the AAV vectors were prepared by the same method and titers 
determined in the same qPCR reaction to ensure that animals received 
comparable doses of the two vectors. Moreover, the CNS neuronal transduction 
profile of AAV-AS was also reproduced in a normal cat, although some 
differences such as the absence of transduced endothelium were apparent, 
which could be the result of variability in promoter efficiency across species. An 
important aspect to consider is that the widespread neuronal transduction profile 
of AAV-AS was achieved with a dose (5x1011 vg/mouse) approximately 8-10 fold 
lower than in previous studies characterizing the CNS tropism of AAV968 and 
other natural AAV capsids70 in adult mice. The extent of striatal neuronal 
transduction far exceeds any previous publication with systemic delivery of any 
AAV capsid, regardless of dose. Nonetheless, it is important to note the neuronal 
transduction properties of this new AAV-AS capsid are not uniform across the 
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brain as evidenced by the considerable difference in percentage of GFP-positive 
neurons between striatum and thalamus.  
 
The variability in neuronal transduction with AAV-AS in different brain structures 
is likely to be determined by the CNS distribution of cell surface receptor(s) used 
by this new AAV vector to cross the BBB and transduce neurons. Glycans with 
terminal galactose have been identified as the primary factor for AAV9 
attachment to the cell surface50, 205 and the galactose-binding domain on the 
AAV9 capsid surface has been identified204. Integrin binding appears to have a 
role in AAV9 transduction213. Nonetheless, the mechanism that AAV9 and other 
AAV capsids use to cross the BBB, or cerebrospinal fluid (CSF)-blood barrier as 
previously suggested69 is presently unknown. To our knowledge, there is no 
evidence suggesting that poly-alanine peptides target the CNS after vascular 
infusion, or are present in proteins such as transferrin or insulin that are known to 
cross the brain through transcytosis. The topological location of the N-terminus of 
AAV VP2 is uncertain since there is no crystallographic information on the 
location of VP1 or VP2 proteins for any of the AAV capsids with characterized 
structures180, 187. A recent study however indicates that the N-terminus of chimeric 
VP2 proteins is exposed on the capsid surface of at least 70% of capsids239, 
suggesting this may also be the case for the poly-alanine peptide in AAV-AS. 
The results from our study on CHO cells show that cell surface binding of AAV-
AS is identical to AAV9 and AAV9.47, suggesting the interaction with glycans 
with exposed terminal galactose residues is not affected by the poly-alanine 
peptide. The impact of the poly-alanine residues, however, on the interaction of 
AAV9.47 capsid with co-receptors on the luminal surface of brain microvascular 
endothelial cells or other cells along the BBB and CSF-blood barrier is presently 
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unknown. Further studies will be necessary to uncover the mechanism that 
underlies this increased efficiency.  
 
The potential of AAV-AS for development of potent therapies for neurological 
diseases is apparent by its efficacy in reducing huntingtin (Htt) mRNA by 40-50% 
in striatum and motor cortex - two structures relevant to HD pathophysiology - 
after a single systemic infusion. Earlier studies investigating direct striatal 
injection of AAV vectors encoding Htt-specific shRNA or microRNAs in adult mice 
have consistently reported no higher than 40-60% silencing of Htt mRNA at the 
injection site110, 111, 350. A recent study investigating the therapeutic efficacy of a 
systemically delivered AAV9-miR vector in HD mouse models was unable to 
demonstrate Htt mRNA knockdown in the brain of transgenic BACHD mice, and 
33% mRNA knockdown in the striatum but no significant difference in the frontal 
cortex of N171-82Q mice upon administration of a higher dose112, which agrees 
well with the extent of knockdown documented in this study with AAV9 vector.  
 
There is an apparent discrepancy between the differential in GFP transduction 
efficiency of striatal neurons between AAV-AS and AAV9 vectors (36% vs <1 %) 
and the comparatively modest increase in Htt knockdown in the same structure 
with AAV-miRHtt vectors. It is key to note that knockdown is a sum effect of all 
transduced cells in a particular structure, and not just the neuronal population. 
This is exemplified by the comparatively smaller 6-15 fold increase in AAV-AS 
transduction compared to AAV9 when measured by vector genome quantification, 
where the contribution of every transduced CNS cell is taken into account. This 
could indicate that AAV9 transduces other cell types to some extent, but the 
resulting GFP expression level from the CBA promoter used in this study is 
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below the detection limit of our immunohistochemical staining. By the same 
measure, it is possible the degree of enhancement of neuronal transduction 
between the two vectors may not be as large as suggested by the histological 
quantification results. Importantly, as mentioned above, AAV-mediated Htt 
silencing in the striatum after direct injection has been reported at a maximum of 
40-60%, even at the site of local injection where the percentage of transduced 
cells is very high. The reasons for this maximum effect are unknown at the 
moment, but could be due to only a fraction of Htt mRNA in CNS cells being 
accessible to the RNAi pathway. Therefore the 33-50% reduction documented by 
systemic infusion of AAV-AS is likely to be near or at the maximum Htt silencing 
possible with AAV vectors engaging the RNAi pathway in the brain, irrespective 
of any further gene transfer efficacy. The use of differing promoters and vector 
doses further confounds drawing any direct quantitative correlation between the 
two experiments. 
 
Treatment of diffuse and multifocal neurological pathologies by direct 
intraparenchymal injection is unlikely to lead to even distribution of the 
therapeutic molecule in the CNS, even with the use of advanced infusion 
techniques such as convection enhanced delivery56, or by injection into axonally 
connected structures 51, 320-322. In contrast, a single systemic infusion of AAV-B1 
can mediate gene transfer to neuronal populations in multiple structures 
throughout the CNS, making it an attractive candidate for development of AAV-
based gene therapies for neurological disorders. AAV-B1 is demonstrably 
superior to AAV9 for CNS transduction (approximately one log higher). Another 
important characteristic of AAV-B1 is the consistency of pan-neuronal 
transduction in both mouse and cat brain, as numerous naturally occurring 
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models of neurodegenerative diseases in the latter intermediate size species are 
often used in the translation of proof-of-concept experiments in mice to clinical 
trials in humans.  
 
In addition to being extremely potent for CNS gene transfer as expected from the 
screening strategy of this study, AAV-B1 is also highly effective for gene transfer 
to a number of peripheral tissues including skeletal muscle, heart and lung. The 
broad transduction profile of AAV-B1 suggests several gene therapy applications, 
including those for systemic correction of monogenic neurometabolic disorders, 
muscular dystrophies and diabetes, as well as disorders involving the alveolar 
epithelium such as surfactant deficiencies. One such potential therapy 
application is for Pompe disease, a lysosomal storage disease that manifests as 
muscular atrophy, cardiorespiratory failure and glycogen storage in motor 
neurons351. AAV9 has limited therapeutic effect in adult Pompe disease mice 352, 
possibly due to inefficient mannose-6-phosphate receptor-mediated enzyme 
uptake in skeletal muscle 353 and insufficient AAV9 gene transfer efficiency. In 
addition, the unique retinal vasculature transduction profile of AAV-B1 may be 
useful for gene therapy of ocular vascular disorders like diabetic retinopathy and 
wet age-related macular degeneration. The higher resistance of AAV-B1 to pre-
existing neutralizing antibodies in pooled human sera suggests that systemic 
gene therapies based on this new capsid may be applicable to a broader 
population of patients. 
 
The isolation of AAV-B1 is the first instance where an AAV capsid capable of 
crossing a non-compromised blood brain barrier (BBB) has been selected from a 
chimeric capsid library. While the AAV-B1 capsid was selected at the lower 
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library dose, it does not exclude the possibility of stochastic selection. This could 
theoretically be resolved by repeating the selection to isolate the same or 
homologous capsid variants. An argument against AAV-B1 being selected 
stochastically, however, is the greater VP3 protein homology between brain-
selected capsids compared to liver-resident variants, which suggests a structure-
function relationship. One or more of the amino acid differences in surface-
exposed domains of AAV-B1 and AAV8 likely account for the difference in 
tropism between these highly homologous capsids, although the present lack of 
structural data for AAV VP1 and VP2 N-terminal regions180, 187 makes it difficult to 
speculate about the contribution of the numerous amino acid differences found in 
those regions to overall tropism. At the cell entry level, AAV-B1 appears to use 
neither sialic acid nor galactose preferentially as its cell surface receptor, similar 
to AAV8 whose primary receptor remains unknown. Further biophysical studies 
for this capsid may shed light on the unique biological properties of AAV-B1. 
 
The mechanisms by which either of the re-engineered vectors AAV-AS and AAV-
B1, or for that matter, even known natural AAV isolates such as AAV9, enter the 
brain after being injected into the vasculature is unknown. Speculation on how 
these modified AAV vectors gain access to the brain parenchyma will be useful 
for development of next generation CNS-targeted gene therapies. 
 
The blood–brain barrier (BBB) provides an obstacle to free diffusion of vascular 
components into the brain parenchyma. In capillaries of peripheral organs, 
endothelial cells are separated by intercellular clefts and fenestra, which allow for 
non-selective diffusion across the capillary wall. In contrast, the BBB comprises 
of a network of specialized non-fenestrated endothelial cells (that have 
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intercellular junctions to restrict movement through inter-endothelial gaps). The 
capillary wall is further fortressed by a laminin-rich basement membrane, 
vascular pericytes, and astrocytic endfeet. Brain capillaries are therefore deficient 
in vesicular transport due to blocked free diffusion across the vessel. Instead, 
entry into the CSF can be achieved primarily in one of three ways: by passive 
diffusion of lipid-soluble molecules; by active receptor-mediated transport of 
water-soluble molecules (such as glucose and amino acids); and by ion channels.  
 
The upper limit of pore size of BBB is <1 nm, which precludes passive transport 
of viruses across the capillary wall. Several viruses have therefore developed 
strategies to move into the nervous system through both circulatory and axonal 
routes. Viruses like human immunodeficiency virus (HIV) employ a ‘Trojan horse’ 
approach by infecting monocytes that pass through the BBB during normal 
turnover of perivascular macrophages or as result of the production of pro-
inflammatory molecules, such as CC-chemokine ligand 2 (CCL2) that 
compromise the BBB. The human T-lymphotropic virus type 1 (HTLV1) binds to 
endothelial receptors such as glucose transporter type 1 (GLUT1), allowing for 
infection of endothelial cells and subsequent BBB leakage by release of pro-
inflammatory mediators. Several other viruses such as Nipah virus, Japanese 
encephalitis virus (JEV), rabies virus, West Nile virus, and mouse adenovirus 
type 1 (MAV-1) also similarly disrupt the tight junction complex by induction of 
inflammatory cytokines or chemokines.  
 
Whether any of these mechanisms are operative in this case is not clear. There 
is no evidence of neuroinflammation upon systemic administration of either re-
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engineered vector or AAV9. It is possible therefore, that other novel mechanisms 
may be involved in AAV transport across the BBB.  
 
Based on earlier reports using capsids with chimeric VP2, it is conceivable that 
the inserted polyalanine is expressed on the surface of the AAV-AS capsid. Such 
a surface exposed hydrophobic residue may change the physical properties of 
the capsid that may contribute to the transcytosis properties of AAV-AS. These 
may be tested in vivo by replacing the 19-mer polyalanine with polymers of other 
hydrophobic amino acids such as leucine, isoleucine and valine. The size and 
site of the polyalanine insertion may also play a role, as insertion of a 5-mer 
polyalanine into loop IV of the AAV2 capsid at site 587 is reported to not impact 
CNS targeting237. It has been reported that AAV capsids generated by the 
peptide insertion method used here, contain capsids that lack chimeric VP2 and 
increase off-targeting239. Though analysis of AAV-AS capsid proteins reveals that 
the peptide-fused VP2 is present, it is unclear what fraction of total capsids has 
all 3 VP proteins. Purification of VP2-containing capsids (by expressing a 
hexahistidine tag along with polyalanine and subsequent Ni2+ column purification, 
for example) could reduce AAV-AS gene transfer to peripheral tissues. 
It is possible that AAV in general, or the two re-engineered capsids described 
here, may be transported across the BBB by ‘piggy-backing’ on receptor-
mediated transcytosis systems, either by binding to known receptors such as 
transferrin receptor (TfR), insulin or insulin-like growth factor receptor and low 
density lipoprotein receptor-related proteins (LRPs), or an yet unknown one. The 
identity of this receptor can be ascertained by ligand-based receptor capture 
methods such as TRICEPS354, a specifically designed reagent comprising of 3 
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orthogonal moieties: one that is coupled to amino groups on the AAV capsid 
surface, a second for the ligand-based capture of glycosylated receptors on brain 
microvascular endothelial cells (BMVECs) that constitute the BBB, and a biotin 
tag for purifying receptor peptides for analysis by quantitative mass spectrometry 
(MS). While not ideal, preliminary studies on the kinetics of AAV transcytosis can 
be performed using in vitro artificial BBB models. 
Conversely, it is possible that these vectors do not change interaction of AAV at 
the BBB, but instead bind differently to serum proteins in the blood. For example, 
polysorbate 80-coated nanoparticles bind to apolipoproteins in the blood and 
therefore could undergo receptor-mediated endocytosis into the brain capillary 
endothelial cells via the LDL receptor family355 and transcytosis into the brain 
parenchyma, which suggest exploring whether a similar phenomenon occurs for 
the polyalanine-coated nanoparticle-sized AAV-AS. This can be resolved by 
screening interacting partners in the serum by co-precipitation experiments. 
Human galectin-3 binding protein was identified as one such serum protein that 
bound to AAV6 and modulated vector distribution following intravenous 
delivery356. No such binding partner, however, has been identified for AAV8 
(closest natural isolate of AAV-B1) or AAV9 (closest natural isolate of AAV-AS). 
 
The question of how to select for an effective AAV capsid for human gene 
transfer remains a central and a particularly complex one. Rodents serve as 
ubiquitously important models for biomedical testing. However, rodents may have 
limited predictive capability for brain studies, as their brain circuitry, cognition and 
behavior differ significantly from humans. Non-human primates (NHPs) may be 
more appropriate for preclinical studies, as they share specialized brain 
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structures implicated in motor, perception and cognition capability (such as an 
expanded frontal cortex357) with humans that have no homolog in any other 
mammal. 
 
However, gene transfer in animal models (which are used to test AAV vectors in 
a preclinical setting) may not translate to human populations. For example, 
systemic administration of AAV2 and AAV8 vectors in hemophilia B patients 
resulted in comparable levels of plasma factor IX expression153, 306, 358. In contrast, 
preclinical data from mouse and non-human primates clearly predict AAV8 to be 
the superior liver gene therapy vector359-361. One approach is to use humanized 
mouse models. These models are repopulated with particular human cell 
populations362, and can be predictive of human transduction in efficacy studies. 
Humanized liver models have been used both as preclinical disease models for 
gene therapy363, and also as a platform to select a chimeric capsid capable of 
enhanced human hepatocyte transduction249, although whether this selected 
capsid is truly superior to natural isolates like AAV8 is debatable341, 364. 
Humanized brain mouse models are rare, primarily due to the embargo on 
research on human/non-human chimeras based on ethical considerations. 
Nevertheless, some models exist, such as human glial progenitor cell-engrafted 
mice that exhibit enhanced synaptic plasticity and learning365. Such models might 
be incredibly valuable to simulate the human brain for preclinical testing. 
However, many concerns exist for using humanized mouse models as predictive 
tools for clinical gene therapy, such as human donor-to-donor variability and 
disparity in extent of engraftment from mouse-to-mouse. Recent efforts in 
recapitulating human diversity in mouse models (such as Diversity Outbred 
mice366 at The Jackson Laboratory) may be useful. Perhaps the biggest 
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drawback of humanized mouse models for AAV capsid and gene therapy studies 
is lack of a human immune system. Human preexisting neutralizing antibodies 
and capsid-specific T cell response, likely lacking in mouse models, inhibit AAV-
mediated transduction in patients. This last factor can be reduced by steroid 
administration prior to AAV infusion. Reconstituting humanized mice models with 
Hu-CD34+ engraftment recapitulating the multilineage human immune system367 
will likely be more predictive of clinical gene therapy outcomes. 
 
In conclusion, AAV-AS and AAV-B1 are the first AAV capsids with superior CNS 
gene transfer properties since the discovery of AAV9 and provide a potent new 
platform for development of novel gene therapies for neurological diseases.   
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